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CLINICAL EVALUATION
Guideline 3.1: Clinical Evaluation
We recommend that for all patients with suspected leg ulcers ﬁtting the deﬁnition of venous leg ulcer, clinical
evaluation for evidence of chronic venous disease be performed. [BEST PRACTICE]
Guideline 3.2: Nonvenous Causes of Leg Ulcers
We recommend identiﬁcation of medical conditions that affect ulcer healing and other nonvenous causes of
ulcers. [BEST PRACTICE]
Guideline 3.3: Wound Documentation
We recommend serial venous leg ulcer wound measurement and documentation. [BEST PRACTICE]
Guideline 3.4: Wound Culture
We suggest against routine culture of venous leg ulcers and only to obtain wound culture specimens when clin-
ical evidence of infection is present. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 3.5: Wound Biopsy
We recommend wound biopsy for leg ulcers that do not improve with standard wound and compression
therapy after 4 to 6 weeks of treatment and for all ulcers with atypical features. [GRADE - 1; LEVEL OF
EVIDENCE - C]
Guideline 3.6: Laboratory Evaluation
We suggest laboratory evaluation for thrombophilia for patients with a history of recurrent venous thrombosis
and chronic recurrent venous leg ulcers. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 3.7: Arterial Testing
We recommend arterial pulse examination and measurement of ankle-brachial index on all patients with venous
leg ulcer. [GRADE - 1; LEVEL OF EVIDENCE - B]
Guideline 3.8: Microcirculation Assessment
We suggest against routine microcirculation assessment of venous leg ulcers but suggest selective consideration
as an adjunctive assessment for monitoring of advanced wound therapy. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 3.9: Venous Duplex Ultrasound
We recommend comprehensive venous duplex ultrasound examination of the lower extremity in all patients
with suspected venous leg ulcer. [GRADE - 1; LEVEL OF EVIDENCE - B]
Guideline 3.10: Venous Plethysmography
We suggest selective use of venous plethysmography in the evaluation of patients with suspected venous leg
ulcer if venous duplex ultrasound does not provide deﬁnitive diagnostic information. [GRADE - 2; LEVEL OF
EVIDENCE - B]
Guideline 3.11: Venous Imaging
We suggest selective computed tomography venography, magnetic resonance venography, contrast venography,
and/or intravascular ultrasound in patients with suspected venous leg ulceration if additional advanced venous
diagnosis is required for thrombotic or nonthrombotic iliac vein obstruction or for operative planning before
open or endovenous interventions. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 3.12: Venous Disease Classiﬁcation
We recommend that all patients with venous leg ulcer be classiﬁed on the basis of venous disease classiﬁcation
assessment, including clinical CEAP, revised Venous Clinical Severity Score, and venous diseaseespeciﬁc quality of
life assessment. [BEST PRACTICE]
Guideline 3.13: Venous Procedural Outcome Assessment
We recommend venous procedural outcome assessment including reporting of anatomic success, venous hemo-
dynamic success, procedure-related minor and major complications, and impact on venous leg ulcer healing. [BEST
PRACTICE]
WOUND CARE
Guideline 4.1: Wound Cleansers
We suggest that venous leg ulcers be cleansed initially and at each dressing change with a neutral, nonirritating,
nontoxic solution, performed with a minimum of chemical or mechanical trauma. [GRADE - 2; LEVEL OF
EVIDENCE - C]
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Guideline 4.2: Débridement
We recommend that venous leg ulcers receive thorough débridement at their initial evaluation to remove obvious
necrotic tissue, excessive bacterial burden, and cellular burden of dead and senescent cells. [GRADE - 1; LEVEL OF
EVIDENCE - B] We suggest that additional maintenance débridement be performed to maintain the appearance
and readiness of the wound bed for healing. [GRADE - 2; LEVEL OF EVIDENCE - B] We suggest that the health
care provider choose from a number of débridement methods, including sharp, enzymatic, mechanical, biologic, and
autolytic. More than one débridement method may be appropriate. [GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 4.3: Anesthesia for Surgical Débridement
We recommend that local anesthesia (topical or local injection) be administered to minimize discomfort asso-
ciated with surgical venous leg ulcer débridement. In selected cases, regional block or general anesthesia may be
required. [GRADE - 1; LEVEL OF EVIDENCE - B]
Guideline 4.4: Surgical Débridement
We recommend that surgical débridement be performed for venous leg ulcers with slough, nonviable tissue, or
eschar. Serial wound assessment is important in determining the need for repeated débridement. [GRADE - 1;
LEVEL OF EVIDENCE - B]
Guideline 4.5 Hydrosurgical Débridement
We suggest hydrosurgical débridement as an alternative to standard surgical débridement of venous leg ulcers.
[GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 4.6: Ultrasonic Débridement
We suggest against ultrasonic débridement over surgical débridement in the treatment of venous leg ulcers.
[GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 4.7: Enzymatic Débridement
We suggest enzymatic débridement of venous leg ulcers when no clinician trained in surgical débridement is
available to débride the wound. [GRADE - 2; LEVEL OF EVIDENCE - C] We do not suggest enzymatic débride-
ment over surgical débridement. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 4.8: Biologic Débridement
We suggest that larval therapy for venous leg ulcers can be used as an alternative to surgical débridement.
[GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 4.9: Management of Limb Cellulitis
We recommend that cellulitis (inﬂammation and infection of the skin and subcutaneous tissue) surrounding the
venous leg ulcer be treated with systemic gram-positive antibiotics. [GRADE - 1; LEVEL OF EVIDENCE - B]
Guideline 4.10: Wound Colonization and Bacterial Bioﬁlms
We suggest against systemic antimicrobial treatment of venous leg ulcer colonization or bioﬁlm without clinical
evidence of infection. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 4.11: Treatment of Wound Infection
We suggest that venous leg ulcers with >1 3 106 CFU/g of tissue and clinical evidence of infection be treated
with antimicrobial therapy. [GRADE - 2; LEVEL OF EVIDENCE - C] We suggest antimicrobial therapy for
virulent or difﬁcult to eradicate bacteria (such as beta-hemolytic streptococci, pseudomonas, and resistant
staphylococcal species) at lower levels of colony-forming units per gram of tissue. [GRADE - 2; LEVEL OF
EVIDENCE - C] We suggest a combination of mechanical disruption and antibiotic therapy as most likely to be
successful in eradicating venous leg ulcer infection. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 4.12: Systemic Antibiotics
We recommend that venous leg ulcers with clinical evidence of infection be treated with systemic antibiotics
guided by sensitivities performed on wound culture. [GRADE - 1; LEVEL OF EVIDENCE - C] Oral antibiotics
are preferred initially, and the duration of antibiotic therapy should be limited to 2 weeks unless persistent evidence
of wound infection is present. [GRADE - 1; LEVEL OF EVIDENCE - C]
Guideline 4.13: Topical Antibiotics for Infected Wounds
We suggest against use of topical antimicrobial agents for the treatment of infected venous leg ulcers.
[GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 4.14: Topical Dressing Selection
We suggest applying a topical dressing that will manage venous leg ulcer exudate and maintain a moist, warm
wound bed. [GRADE - 2; LEVEL OF EVIDENCE - C] We suggest selection of a primary wound dressing that will
absorb wound exudate produced by the ulcer (alginates, foams) and protect the periulcer skin. [GRADE - 2;
LEVEL OF EVIDENCE - B]
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Guideline 4.15: Topical Dressings Containing Antimicrobials
We recommend against the routine use of topical antimicrobial-containing dressings in the treatment of nonin-
fected venous leg ulcers. [GRADE - 2; LEVEL OF EVIDENCE - A]
Guideline 4.16: Periulcer Skin Management
We suggest application of skin lubricants underneath compression to reduce dermatitis that commonly affects
periulcer skin. [GRADE - 2; LEVEL OF EVIDENCE -C] In severe cases of dermatitis associated with venous leg
ulcers, we suggest topical steroids to reduce the development of secondary ulcerations and to reduce the symptoms
of dermatitis. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 4.17: Anti-inﬂammatory Therapies
We suggest against use of anti-inﬂammatory therapies for the treatment of venous leg ulcers. [GRADE - 2;
LEVEL OF EVIDENCE - C]
Guideline 4.18: Indications for Adjuvant Therapies
We recommend adjuvant wound therapy options for venous leg ulcers that fail to demonstrate improvement
after a minimum of 4 to 6 weeks of standard wound therapy. [GRADE - 1; LEVEL OF EVIDENCE - B]
Guideline 4.19: Split-thickness Skin Grafting
We suggest against split-thickness skin grafting as primary therapy in treatment of venous leg ulcers. [GRADE -
2; LEVEL OF EVIDENCE - B] We suggest split-thickness skin grafting with continued compression for selected
large venous leg ulcers that have failed to show signs of healing with standard care for 4 to 6 weeks. [GRADE - 2;
LEVEL OF EVIDENCE - B]
Guideline 4.20: Cellular Therapy
We suggest the use of cultured allogeneic bilayer skin replacements (with both epidermal and dermal layers) to
increase the chances for healing in patients with difﬁcult to heal venous leg ulcers in addition to compression ther-
apy in patients who have failed to show signs of healing after standard therapy for 4 to 6 weeks. [GRADE - 2;
LEVEL OF EVIDENCE - A]
Guideline 4.21: Preparation for Cellular Therapy
We suggest a therapeutic trial of appropriate compression and wound bed moisture control before application
of cellular therapy. [GRADE - 2; LEVEL OF EVIDENCE - C] We recommend that adequate wound bed prepa-
ration, including complete removal of slough, debris, and any necrotic tissue, be completed before the application
of a bilayered cellular graft. [GRADE - 1; LEVEL OF EVIDENCE - C] We recommend additional evaluation and
management of increased bioburden levels before the application of cellular therapy. [GRADE - 1; LEVEL OF
EVIDENCE - C]
Guideline 4.22: Frequency of Cellular Therapy Application
We suggest reapplication of cellular therapy as long as the venous leg ulcer continues to respond on the basis of
wound documentation. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 4.23: Tissue Matrices, Human Tissues, or Other Skin Substitutes
We suggest the use of a porcine small intestinal submucosal tissue construct in addition to compression therapy
for the treatment of venous leg ulcers that have failed to show signs of healing after standard therapy for 4 to 6
weeks. [GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 4.24: Negative Pressure Therapy
We suggest against routine primary use of negative pressure wound therapy for venous leg ulcers. [GRADE - 2;
LEVEL OF EVIDENCE - C]
Guideline 4.25: Electrical Stimulation
We suggest against electrical stimulation therapy for venous leg ulcers. [GRADE - 2; LEVELOF EVIDENCE - C]
Guideline 4.26: Ultrasound Therapy
We suggest against routine ultrasound therapy for venous leg ulcers. [GRADE - 2; LEVEL OF EVIDENCE - B]
COMPRESSION
Guideline 5.1: CompressiondUlcer Healing
In a patient with a venous leg ulcer, we recommend compression therapy over no compression therapy to in-
crease venous leg ulcer healing rate. [GRADE - 1; LEVEL OF EVIDENCE - A]
Guideline 5.2: CompressiondUlcer Recurrence
In a patient with a healed venous leg ulcer, we suggest compression therapy to decrease the risk of ulcer recur-
rence. [GRADE - 2; LEVEL OF EVIDENCE - B]
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Guideline 5.3: Multicomponent Compression Bandage
We suggest the use of multicomponent compression bandage over single-component bandages for the treat-
ment of venous leg ulcers. [GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 5.4: CompressiondArterial Insufﬁciency
In a patient with a venous leg ulcer and underlying arterial disease, we do not suggest compression bandages or
stockings if the ankle-brachial index is 0.5 or less or if absolute ankle pressure is less than 60 mmHg. [GRADE - 2;
LEVEL OF EVIDENCE - C]
Guideline 5.5: Intermittent Pneumatic Compression
We suggest use of intermittent pneumatic compression when other compression options are not available,
cannot be used, or have failed to aid in venous leg ulcer healing after prolonged compression therapy. [GRADE - 2;
LEVEL OF EVIDENCE - C]
OPERATIVE/ENDOVASCULAR MANAGEMENT
Guideline 6.1: Superﬁcial Venous Reﬂux and Active Venous Leg UlcerdUlcer Healing
In a patient with a venous leg ulcer (C6) and incompetent superﬁcial veins that have axial reﬂux directed to the
bed of the ulcer, we suggest ablation of the incompetent veins in addition to standard compressive therapy to
improve ulcer healing. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.2: Superﬁcial Venous Reﬂux and Active Venous Leg UlcerdPrevent Recurrence
In a patient with a venous leg ulcer (C6) and incompetent superﬁcial veins that have axial reﬂux directed to the
bed of the ulcer, we recommend ablation of the incompetent veins in addition to standard compressive therapy to
prevent recurrence. [GRADE - 1; LEVEL OF EVIDENCE - B]
Guideline 6.3: Superﬁcial Venous Reﬂux and Healed Venous Leg Ulcer
In a patient with a healed venous leg ulcer (C5) and incompetent superﬁcial veins that have axial reﬂux directed
to the bed of the ulcer, we recommend ablation of the incompetent veins in addition to standard compressive ther-
apy to prevent recurrence. [GRADE - 1; LEVEL OF EVIDENCE - C]
Guideline 6.4: Superﬁcial Venous Reﬂux With Skin Changes at Risk for Venous Leg Ulcer (C4b)
In a patient with skin changes at risk for venous leg ulcer (C4b) and incompetent superﬁcial veins that have axial
reﬂux directed to the bed of the affected skin, we suggest ablation of the incompetent superﬁcial veins in addition to
standard compressive therapy to prevent ulceration. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.5: Combined Superﬁcial and Perforator Venous Reﬂux With or Without Deep Venous Reﬂux and
Active Venous Leg Ulcer
In a patient with a venous leg ulcer (C6) and incompetent superﬁcial veins that have reﬂux to the ulcer bed in
addition to pathologic perforating veins (outward ﬂow of >500 ms duration, with a diameter of >3.5 mm) located
beneath or associated with the ulcer bed, we suggest ablation of both the incompetent superﬁcial veins and
perforator veins in addition to standard compressive therapy to aid in ulcer healing and to prevent recurrence.
[GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.6: Combined Superﬁcial and Perforator Venous Reﬂux With or Without Deep Venous Disease and
Skin Changes at Risk for Venous Leg Ulcer (C4b) or Healed Venous Ulcer (C5)
In a patient with skin changes at risk for venous leg ulcer (C4b) or healed venous ulcer (C5) and incompetent
superﬁcial veins that have reﬂux to the ulcer bed in addition to pathologic perforating veins (outward ﬂow of >500
ms duration, with a diameter of >3.5 mm) located beneath or associated with the healed ulcer bed, we suggest abla-
tion of the incompetent superﬁcial veins to prevent the development or recurrence of a venous leg ulcer. [GRADE -
2; LEVEL OF EVIDENCE - C] Treatment of the incompetent perforating veins can be performed simultaneously
with correction of axial reﬂux or can be staged with re-evaluation of perforator veins for persistent incompetence
after correction of axial reﬂux. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.7: Pathologic Perforator Venous Reﬂux in the Absence of Superﬁcial Venous Disease, With or
Without Deep Venous Reﬂux, and a Healed or Active Venous Ulcer
In a patient with isolated pathologic perforator veins (outward ﬂow of >500 ms duration, with a diameter of
>3.5 mm) located beneath or associated with the healed (C5) or active ulcer (C6) bed regardless of the status of the
deep veins, we suggest ablation of the “pathologic” perforating veins in addition to standard compression therapy
to aid in venous ulcer healing and to prevent recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]
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Guideline 6.8: Treatment Alternatives for Pathologic Perforator Veins
For those patients who would beneﬁt from pathologic perforator vein ablation, we recommend treatment by
percutaneous techniques that include ultrasound-guided sclerotherapy or endovenous thermal ablation (radiofre-
quency or laser) over open venous perforator surgery to eliminate the need for incisions in areas of compromised
skin. [GRADE - 1; LEVEL OF EVIDENCE - C]
Guideline 6.9: Infrainguinal Deep Venous Obstruction and Skin Changes at Risk for Venous Leg Ulcer (C4b),
Healed (C5) or Active (C6) Venous Leg Ulcer
In a patient with infrainguinal deep venous obstruction and skin changes at risk for venous leg ulcer (C4b),
healed venous leg ulcer (C5), or active venous leg ulcer (C6), we suggest autogenous venous bypass or endophle-
bectomy in addition to standard compression therapy to aid in venous ulcer healing and to prevent recurrence.
[GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.10: Deep Venous Reﬂux With Skin Changes at Risk for Venous Leg Ulcer (C4b), Healed (C5) or
Active (C6) Venous Leg UlcerdLigation
In a patient with infrainguinal deep venous reﬂux and skin changes at risk for venous leg ulcer (C4b), healed
venous leg ulcer (C5), or active venous leg ulcer (C6), we suggest against deep vein ligation of the femoral or popli-
teal veins as a routine treatment. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.11: Deep Venous Reﬂux With Skin Changes at Risk for Venous Leg Ulcer (C4b), Healed (C5) or
Active (C6) Venous Leg UlcerdPrimary Valve Repair
In a patient with infrainguinal deep venous reﬂux and skin changes at risk for venous leg ulcer (C4b), healed
venous leg ulcer (C5), or active venous leg ulcer (C6), we suggest individual valve repair for those who have axial
reﬂux with structurally preserved deep venous valves in addition to standard compression therapy to aid in venous
ulcer healing and to prevent recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.12: Deep Venous Reﬂux With Skin Changes at Risk for Venous Leg Ulcer (C4b), Healed (C5) or
Active (C6) Venous Leg UlcerdValve Transposition or Transplantation
In a patient with infrainguinal deep venous reﬂux and skin changes at risk for venous leg ulcer (C4b), healed
venous leg ulcer (C5), or active venous leg ulcer (C6), we suggest valve transposition or transplantation for those
with absence of structurally preserved axial deep venous valves when competent outﬂow venous pathways are
anatomically appropriate for surgical anastomosis in addition to standard compression therapy to aid in venous
leg ulcer healing and to prevent recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.13: Deep Venous Reﬂux With Skin Changes at Risk for Venous Leg Ulcer (C4b), Healed (C5) or
Active (C6) Venous Leg UlcerdAutogenous Valve Substitute
In a patient with infrainguinal deep venous reﬂux and skin changes at risk for venous leg ulcer (C4b), healed
venous leg ulcer (C5), or active venous leg ulcer (C6), we suggest consideration of autogenous valve substitutes
by surgeons experienced in these techniques to facilitate ulcer healing and to prevent recurrence in those with
no other option available in addition to standard compression therapy to aid in venous ulcer healing and to prevent
recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.14: Proximal Chronic Total Venous Occlusion/Severe Stenosis With Skin Changes at Risk for
Venous Leg Ulcer (C4b), Healed (C5) or Active (C6) Venous Leg UlcerdEndovascular Repair
In a patient with inferior vena cava or iliac vein chronic total occlusion or severe stenosis, with or without lower
extremity deep venous reﬂux disease, that is associated with skin changes at risk for venous leg ulcer (C4b), healed
venous leg ulcer (C5), or active venous leg ulcer (C6), we recommend venous angioplasty and stent recanalization in
addition to standard compression therapy to aid in venous ulcer healing and to prevent recurrence. [GRADE - 1;
LEVEL OF EVIDENCE - C]
Guideline 6.15: Proximal Chronic Venous Occlusion/Severe Stenosis (Bilateral) With Recalcitrant Venous
UlcerdOpen Repair
In a patient with inferior vena cava or iliac vein chronic occlusion or severe stenosis, with or without lower ex-
tremity deep venous reﬂux disease, that is associated with a recalcitrant venous leg ulcer and failed endovascular
treatment, we suggest open surgical bypass with use of an externally supported expanded polytetraﬂuoroethylene
graft in addition to standard compression therapy to aid in venous leg ulcer healing and to prevent recurrence.
[GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.16: Unilateral Iliofemoral Venous Occlusion/Severe Stenosis With Recalcitrant Venous Ulcerd
Open Repair
In a patient with unilateral iliofemoral venous occlusion/severe stenosis with recalcitrant venous leg ulcer for
whom attempts at endovascular reconstruction have failed, we suggest open surgical bypass with use of saphenous
vein as a cross-pubic bypass (Palma procedure) to aid in venous ulcer healing and to prevent recurrence. A synthetic
graft is an alternative in the absence of autogenous tissue. [GRADE - 2; LEVEL OF EVIDENCE - C]
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Guideline 6.17: Proximal Chronic Total Venous Occlusion/Severe Stenosis (Bilateral or Unilateral) With
Recalcitrant Venous UlcerdAdjunctive Arteriovenous Fistula
For those patients who would beneﬁt from an open venous bypass, we suggest the addition of an adjunctive
arteriovenous ﬁstula (4-6 mm in size) as an adjunct to improve inﬂow into autologous or prosthetic crossover by-
passes when the inﬂow is judged to be poor to aid in venous leg ulcer healing and to prevent recurrence. [GRADE -
2; LEVEL OF EVIDENCE - C]
ANCILLARY MEASURES
Guideline 7.1: Nutrition Assessment and Management
We recommend that nutrition assessment be performed in any patient with a venous leg ulcer who has evidence
of malnutrition and that nutritional supplementation be provided if malnutrition is identiﬁed. [BEST PRACTICE]
Guideline 7.2: Systemic Drug Therapy
For long-standing or large venous leg ulcer, we recommend treatment with either pentoxifylline or micronized pu-
riﬁed ﬂavonoid fraction used in combination with compression therapy. [GRADE - 1; LEVEL OF EVIDENCE - B]
Guideline 7.3: Physiotherapy
We suggest supervised active exercise to improve muscle pump function and to reduce pain and edema in
patients with venous leg ulcers. [GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 7.4: Manual Lymphatic Drainage
We suggest against adjunctive lymphatic drainage for healing of the chronic venous leg ulcers. [GRADE - 2;
LEVEL OF EVIDENCE - C]
Guideline 7.5: Balneotherapy
We suggest balneotherapy to improve skin trophic changes and quality of life in patients with advanced venous
disease. [GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 7.6: Ultraviolet light
We suggest against use of ultraviolet light for the treatment of venous leg ulcers. [GRADE - 2; LEVEL OF
EVIDENCE - C]
PRIMARY PREVENTION
Guideline 8.1: Primary PreventiondClinical CEAP C3-4 Primary Venous Disease
In patients with clinical CEAP C3-4 disease due to primary valvular reﬂux, we recommend compression, 20 to
30 mm Hg, knee or thigh high. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 8.2: Primary PreventiondClinical CEAP C1-4 Post-thrombotic Venous Disease
In patients with clinical CEAP C1-4 disease related to prior deep venous thrombosis (DVT), we recommend
compression, 30 to 40 mm Hg, knee or thigh high. [GRADE - 1; LEVEL OF EVIDENCE - B]
Guideline 8.3. Primary PreventiondAcute DVT Treatment
As post-thrombotic syndrome is a common preceding event for venous leg ulcers, we recommend current
evidence-based therapies for acute DVT treatment. [GRADE - 1; LEVEL OF EVIDENCE - B] We suggest use of
low-molecular-weight heparin over vitamin K antagonist therapy of 3-month duration to decrease post-
thrombotic syndrome. [GRADE - 2; LEVEL OF EVIDENCE - B] We suggest catheter-directed thrombolysis in pa-
tients with low bleeding risk with iliofemoral DVT of duration <14 days. [GRADE - 2; LEVELOF EVIDENCE - B]
Guideline 8.4: Primary PreventiondEducation Measures
In patients with C1-4 disease, we suggest patient and family education, regular exercise, leg elevation when at
rest, careful skin care, weight control, and appropriately ﬁtting foot wear. [BEST PRACTICE]
Guideline 8.5: Primary PreventiondOperative Therapy
In patients with asymptomatic C1-2 disease from either primary or secondary causes, we suggest against pro-
phylactic interventional therapies to prevent venous leg ulcer. [GRADE - 2; LEVEL OF EVIDENCE - C]
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GUIDELINES
Guidelines present a synthesis of evidence-based rec-
ommendations for the diagnosis and treatment of a speciﬁc
medical condition.1 The value of a guideline is that it pro-
vides consistency among treatment protocols given to pa-
tients, resulting in improved efﬁcacy and the quality ofcare and reduced cost. The need for cost containment of
health care has placed the development and implementa-
tion of clinical care guidelines as a high priority for health
care systems Both the prevalence of venous leg ulcers
(VLUs)d1% to 1.5% of the populationdand the eco-
nomic impact of VLUs are two compelling reasons to
develop a speciﬁc guideline for this problem.2 The care
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that an agreed on “best practice” algorithm can maximize
the quality and effectiveness of care while minimizing cost
and resource use.3 Moreover, VLUs are associated with
prolonged disability, important socioeconomic impact,
and signiﬁcant psychosocial morbidity. Because approxi-
mately 50% of VLUs may recur within 10 years, they are
marked by a signiﬁcant component of chronicity, which
compounds their economic impact and need for repetitive
care. VLUs also can be painful, so that a patient’s ability
to work may be compromised, and can also affect the
retired segments of the population, thereby compounding
both the indirect and direct costs of treating VLU.
Epidemiology of Venous Leg Ulcers. VLUs are the
most common ulceration on the lower extremity and ac-
count for 70% of all leg ulcers.4 Various estimates have
been made from observational studies on the prevalence of
VLU, ranging between 0.06% and 2%. The Edinburgh
study, which was a cross-sectional study of a random
sample of more than 1500 people between the ages of 18
and 64 years, provided an estimate of VLU prevalence of
1%.5 This lower prevalence contrasts with the higher
prevalence of an earlier study (2.7% clinical CEAP C5/
C6), which was based on a questionnaire and photographs
of the legs of the participants.6 As in the Edinburgh study,
VLU prevalence increased with age. Two other studies
examined large populations. Approximately 40,000 Polish
patients underwent clinical evaluation and interviews by a
variety of health care professionals in a multicenter study
showing a 1.5% prevalence of C5/C6 disease.7 Another
cross-sectional study carried out in France addressed a
subset of patients from a larger study of Raynaud patients.
All of the 400 patients were evaluated by vascular medicine
specialists. C5 disease was higher in men (5.4%) than in
women (2.7%), but the investigators observed no open
ulcers.8 The most detailed information comes from the
Bonn Vein Longitudinal Study initiated by the German
Ministry of Health.9 More than 3000 participants were
randomly identiﬁed between the ages of 18 and 79 years.
Advanced chronic venous reﬂux (chronic venous insufﬁ-
ciency [CVI]) was found in 0.6% with a healed VLU (C5)
and in 0.1% with an open VLU for a total of 0.7%. This
longitudinal study documented a decrease in advanced
CVI (C4-C6), which may be related to a more compre-
hensive use of diagnostic and therapeutic modalities for
CVI. Because of the high prevalence of venous disease, the
AVF National Venous Screening Program was established
in the United States to increase awareness. The program
screened 2234 individuals and identiﬁed varicose veins in
more than 30% of participants and more advanced venous
disease (C4-C6) in more than 10%.10 It has been estimated
that approximately 2.5 million people suffer from CVI in
the United States, and of those, about 20% develop venous
ulcers.11
Economic Impact. The overall cost of treating VLU
approaches 1% of the health care budget of some western
European countries; in the United Kingdom, the annual
cost is estimated to range from ₤300 million to ₤600million per year.12,13 In the United States, $2.5 billion
was expended for the treatment of VLUs in more than 6
million patients.14 A recent study on the cost of treating
VLUs in Germany demonstrated that mean cost averaged
V9569 per patient per year, and 92% of this expenditure
was related to direct costs.15 Although the majority of
patients with VLUs can be treated on an outpatient basis
and are infrequently hospitalized except for complications,
the direct cost of treating VLUs in the United States has
been estimated to be $2500 per month per patient.16 In
the ambulatory setting, the direct cost of this care is related
to (1) technical (facility) costs and professional reim-
bursement (physicians); (2) labor costs (nurses and para-
medical personnel) for wound care treatments, which are
the major driver of costs; and (3) medications as well as
specialized wound dressings and compression garments. A
key determinant of the costs of treating VLU is the effec-
tiveness of treatmentdnot only how rapidly the ulcer heals,
but also whether the ulcer recurs. For example, a more
expensive wound dressing may have an economic advan-
tage for overall care because of more rapid healing of the
VLU with less duration of product use and attendant labor
costs.
To determine the actual costs of treating VLUs during
a 1-year period, a recent study examined a cohort of 84 pa-
tients with nonhealing VLUs (CEAP C6) who presented
to a wound clinic. All patients were treated in a wound
center by ﬁve vascular surgeons with a minimum follow-
up of 6 months (median, 368 days; 336-483).17 Actual
costs (not charges) were obtained for outpatient and inpa-
tient facility, visiting nurse services, and physician practice
group to yield true cost. The proportion and time to com-
plete healing of VLU were determined to calculate time to
healing as well as ulcer-free intervals. Cost/ulcer-free days
and cost to complete healing for the entire follow-up
period were carried out with univariate analysis of factors
affecting cost. The mean total cost of treating VLU during
this follow-up period was $15,732. A total of 50 patients
(60%) healed their VLU without recurrence in a mean
time of 122 days (6-379 days) at a mean cost of
$10,563 ($430-$50,967). Signiﬁcant contributing factors
were outpatient facility fees ($10,332) and visiting nurse
services ($11,365) related to extended treatment of the
open VLU. Patients who failed to heal their ulcer during
the duration of this study (20%) had a threefold increase
in their costs ($33,907). Those patients who had recur-
rence of their VLU (N ¼ 17; 20%) during the follow-up
period had a total mean cost of $12,760. Inpatient admis-
sion, of which nearly two thirds was for treatment of infec-
tions that were resistant to therapy in an outpatient setting,
markedly increased costs ($33,629). By contrast, VLU
treated with surgical intervention of the superﬁcial venous
system did not signiﬁcantly increase total cost over that of
patients receiving best medical therapy ($11,960 vs
$12,304) but signiﬁcantly reduced recurrence rates (34%
vs 5%). By, contrast, patients treated for outﬂow obstruc-
tion had a twofold increase in total costs ($24,241 vs
$11,960).
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Leg Ulcer Care. The value of developing and implement-
ing clinical practice guidelines should be to provide quality
of care without a dramatic increase in cost. This focus on
“best outcomes for the most reasonable health care dollar”
has stimulated many organizations, such as the SVS and
AVF, to develop and to promote a uniﬁed set of guidelines
for treatment of chronic diseases, such as VLUs. An
evidence-based analysis of treatment options should
decrease the variations in care while at the same time
ensuring that resources are used in an optimal manner.
Specialty societies, as in the current SVS and AVF guideline,
develop clinical practice guidelines either by independent
review of available studies or by employing evidence from
technology assessments and other published guidelines. For
the development of comprehensive clinical practice guide-
lines on VLUs that would be of value to providers and the
health care system in general, an expert panel needs to
evaluate the efﬁcacy of individual wound care dressings,
surgery, or compression products, as demonstrated in ran-
domized controlled trials (RCTs). In addition, large case
series and expert opinion are also used as evidence, although
of lower quality. The value of these clinical practice guide-
lines on VLUs is that they sift through the massive amount
of data surrounding the management of VLU and provide a
consensus on the evidence, thereby streamlining resources.18
Survey of the Use of Venous Leg Ulcer Guidelines
by Various Health Care Systems. Whereas there are
obvious advantages to the development and use of guide-
lines on VLU, implementation can be a challenge. Such
“best practices” can be construed as antithetical to the au-
tonomy of clinical practitioners, who make decisions on
the basis of individual patients. These factors may prevent to-
tal “buy in” by physicians. Moreover, a set of guidelines can
be interpreted as instituting the rigid perspectives of policy
makers on health care delivery for a speciﬁc disease process.
To determine the current status of implementation of guide-
lines or a speciﬁc best practices protocol for the management
of VLUs, several large health care systems in the United
States as well as in Canada and Europe were surveyed.18
Vascular units in these facilities were queried on whether a
speciﬁc set of guidelines or protocols was uniformly applied
for two conditions: (1) the treatment of VLU and (2) the
prevention of a post-thrombotic limb. This survey demon-
strated that guidelines for VLU care are infrequently used by
a select group of academic health care systems in the United
States (20%), but the majority of single-payer systems in
Canada and Europe (82%) employed a VLU guideline. By
contrast, the use of guidelines for the prevention of the post-
thrombotic limb after deep venous thrombosis (DVT) was
comparable between the United States and other countries.
This low use of VLU guidelines in the United States
occurred despite the availability of guidelines developed by
various societies. This ﬁnding emphasizes the need for both
a comprehensive and a well-promoted guideline for VLUs.
Efﬁcacy of Current Guidelines for Venous Leg
Ulcer. Whereas there are various treatment protocols for
VLUs, they differ in efﬁcacy, quality, and cost. A moreuniform method of treatment that has been agreed on by a
panel of experts and based on clinical evidence for efﬁcacy
may improve therapeutic effectiveness and possibly reduce
cost. Several studies have demonstrated that after the institu-
tion of a VLU guideline, there were improvements in both
the ulcer healing and recurrence rate and a subsequent
reduced resource use with lowering of treatment costs,
thereby supporting adoption of VLU guidelines.18 Olson
et al demonstrated that ulcer healing rate was markedly
improved in a Veterans Hospital population of 155 patients
with VLU if guideline recommendations were followed.
During a 5-year period, patients who received dressings that
provided a moist wound healing environment and compres-
sion for 80% of their visits were more likely to heal than those
who did not comply (<80%; relative risk [RR], 2.52; 95%
conﬁdence interval [CI], 1.53-4.16).19 In a combined study
population of patients from the United Kingdom and the
United States, patients who were treated for VLUs by a
treatment protocol had a 2 times and a 6.5 times greater
likelihood of ulcer healing if the guidelines were followed
(P < .01). Moreover, the median costs were reduced with
adherence to VLU guidelines (P < .01).20 Finally, in a lon-
gitudinal cross-sectional Swedish study of patients in Skar-
aborg County (population 254,111), the epidemiology of leg
ulcers and of VLUs in particular was deﬁned in 1988 before
the implementation of a VLU treatment protocol. 21 The
initial point prevalence (proportion with an ulcer at any point
of time, time period usually shorter than 3 months) for open
VLUs was 0.16% and overall (C5 and C6) was 0.5%. Their
protocol for VLU management emphasized early Doppler-
aided diagnosis, organized care pathways, and especially
surgery for superﬁcial venous incompetence. The effective-
ness of the VLU guidelines was judged by the reduction in
the point prevalence of VLUs from 1990 to 2005. The
institution of guidelines and concomitant implementation of
county-wide care plans, based on these guidelines, resulted in
a relative risk for VLU of 46%.22
Objective of SVS and AVF Clinical Practice
Guidelines for Venous Leg Ulcer Management. In
2011, SVS and AVF produced clinical practice guidelines
for the care of patients with varicose veins and associated
venous disease.23 Although there were some elements of
VLU care within this document, most of the emphasis of
this guideline was on varicose vein management. In 2012,
SVS and AVF clinical practice guidelines addressing early
thrombus removal strategies for acute venous thrombosis
were published.24 Again, whereas there is some crossover
regarding the impact of early venous thrombosis on
restored venous patency, potential preserved valvular
function, and decreased post-thrombotic morbidity, there
was little direct attention on VLUs. The objective of the
current SVS and AVF clinical practice guidelines is to focus
on complete management of VLUs at all levels of care
based on strength and quality of supporting evidence to
guide speciﬁc recommendations. Combined with these
other SVS and AVF clinical practice guidelines, a more
complete evidence-based strategy is available for manage-
ment of patients with chronic venous disease.
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GUIDELINES
The Institute of Medicine, in Clinical Practice Guide-
lines We Can Trust, has deﬁned clinical practice guidelines
as “systematically developed statements to assist the practi-
tioner and patient decisions about appropriate healthcare
for speciﬁc clinical circumstances.”25 The underlying prin-
ciple is to use evidence-based medicine to the greatest
extent to develop these guidelines so that the assessment
of the optimal treatment plan is based on the best current
available knowledge. Evidence-based medicine allows one
to assess the statistical strength of a treatment or interven-
tion and, most important, reduces bias in evaluating a
particular therapy.26 Bias is deﬁned as the predisposition
of prejudice toward either the experimental or control
group, which can lead to either an overestimation or an un-
derestimation of the true beneﬁts and harm of the interven-
tion.27 This method reduces uncertainty, which is the
largest single cause of misinterpretation of data.28 This
process has been further stated in the recent Institute of
Medicine document: “Hence, critically appraised and syn-
thesized scientiﬁc evidence has become fundamental to
clinical practice. At the same time, and particularly under
conditions of uncertainty regarding optimal decisions,
clinician experiential knowledge and skill (the “art of med-
icine”) and patient values and preferences remain essential
contributors to quality healthcare practice, in a complex
interplay with science.”25
The Venous Ulcer Guidelines Committee was orga-
nized through cooperation between the SVS and AVF.
The Venous Ulcer Guidelines Committee was divided
into six sub-committee sections each headed by a chair:
diagnosis; compression; surgery/endovascular; wound
care; ancillary; and prevention. The overall committee
then developed a series of key clinical questions to guide
the overall approach for the guideline document: (1)
What is the best treatment for active (CEAP C6) venous ul-
cer? (2) What is the best treatment for healed venous ulcer
(CEAP C5)? (3) What is the best method for preventing
recurrence of venous ulcers? and (4) Can progression
from CEAP C4 to CEAP C6/C5 be prevented? The
Venous Ulcer Guidelines Committee addressed the optimal
approach to be used for their speciﬁc section from four gen-
eral approaches: (1) de novo development, in which a
completely novel recommendation is developed from a sys-
tematic and meta-analysis review of the literature; (2) build
on existing guidelines with a complementary full-literature
search update; (3) adapt guidelines from existing guidelines;
and (4) total adoption of existing guidelines.18 The need for
a systematic and meta-analysis review was determined by
each section team and then agreed on by the entire commit-
tee. Each section was categorized by the type of guideline
development required. All guidelines were developed by
building on existing guidelines with a complementary liter-
ature search by the section sub-committee.
In this process of guideline development for VLUs, the
Venous Ulcer Guidelines Committee also reviewed priorpublished consensus documents and the AVF report from
the 2006 Venous Summit and the 2009 Paciﬁc Vascular
Symposium, whose purpose was to reduce the incidence
of venous ulcer during the next decade by 50%.29 In a pre-
vious systematic review of recently published venous ulcer
guidelines, 14 venous ulcer guidelines were identiﬁed
worldwide.18 This review showed that there was a high de-
gree of agreement among the 14 VLU guidelines on rec-
ommendations for compression (72%), dressings (72%),
pentoxifylline (73%), prevention of recurrence by below-
knee stockings (70%), and surgery (82%). There was a
low proportion of agreement in the areas of diagnosis, clin-
ical evaluation, and venous Doppler and duplex ultrasound;
in elements of wound care: measurement of the wound,
washing of the wound, débridement, and speciﬁc type of
wound dressing; and ﬁnally in adjunctive measures: the
use of skin grafts and physical therapy to promote ankle
mobility with enhancement of the calf muscle pump.
Several areas of “controversy” were identiﬁed that had
not been particularly addressed in previous guidelines:
new innovative, less invasive VLU therapies; the role of iliac
obstruction and occlusion with the need for diagnosis by
intravascular ultrasound and subsequent monitoring of
stenting by this technique; when and by what methods
to treat perforators; the need for physical therapy to pro-
mote ankle mobility and function of the calf muscle
pump; the role of advanced dressings; and preventing pro-
gression to VLU. These areas received special attention in
review for the current guidelines.
The surgery/endovascular and compression sections
were selected for a de novo development of speciﬁc guide-
line recommendations based on several of these key ques-
tions. For additional systematic review involving these
critical areas, the Venous Ulcer Guidelines Committee
commissioned an independent group of researchers to
conduct two systematic reviews to evaluate the effective-
ness of different compression strategies and endovascular
and open surgical approaches. The Committee helped
develop a priori the protocols of these reviews in terms of
outcome selection and criteria for including studies with
additional analysis by the Knowledge and Evaluations
Research Unit at the Mayo Clinic (Rochester, Minn).30,31
In the literature review, several processes were used to
minimize heterogeneity:
- Languagedall would be included.
- Type of Studies Revieweddrandomized controlled
trials, controlled clinical trials with cohort, and retro-
spective large observational case series. The studies
should be published in peer-reviewed journals.
- Target Audiencedthis Guideline document is in-
tended for specialists who treat vascular disease and
wounds.
Through an iterative process, the committee developed
guidelines based on the grading of recommendation assess-
ment, development, and evaluation (GRADE) system
(Table I).32,33 The strength of the recommendations is
Table I. GRADE recommendations based on level of evidence
Grade Description of recommendation Beneﬁt vs risk
Methodologic quality of
supporting evidence Implications
1A Strong recommendation,
high-quality evidence
Beneﬁts clearly outweigh risk
and burdens, or vice versa
RCTs without important
limitations or overwhelming
evidence from observational
studies
Strong recommendation, can
apply to most patients in
most circumstances without
reservation
1B Strong recommendation,
moderate-quality evidence
Beneﬁts clearly outweigh risk
and burdens, or vice versa
RCTs with important
limitations (inconsistent
results, methodologic ﬂaws,
indirect, or imprecise) or
exceptionally strong
evidence from observational
studies
Strong recommendation, can
apply to most patients in
most circumstances without
reservation
1C Strong recommendation, low-
quality or very-low-quality
evidence
Beneﬁts clearly outweigh risk
and burdens, or vice versa
Observational studies or case
series
Strong recommendation but
may change when higher
quality evidence becomes
available
2A Weak recommendation, high-
quality evidence
Beneﬁts closely balanced with
risks and burdens
RCTs without important
limitations or overwhelming
evidence from observational
studies
Weak recommendation, best
action may differ depending
on circumstances or
patients’ or societal values
2B Weak recommendation,
moderate-quality evidence
Beneﬁts closely balanced with
risks and burdens
RCTs with important
limitations (inconsistent
results, methodologic ﬂaws,
indirect, or imprecise) or
exceptionally strong
evidence from observational
studies
Weak recommendation, best
action may differ depending
on circumstances or
patients’ or societal values
2C Weak recommendation, low-
quality or very-low-quality
evidence
Uncertainty in the estimates of
beneﬁts and risk, and
burdens; Risk, beneﬁt, and
burdens may be closely
balanced
Observational studies or case
series
Very weak recommendations;
Other alternatives may be
reasonable
RCTs, Randomized controlled trials.
Modiﬁed from Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of
evidence in clinical guidelines: Report from an American College of Chest Physicians task force. Chest 2006;129:174-81.
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mendation, (2) harm/beneﬁt ratio of the therapy (eg,
minimally invasive intervention with few morbid events
and a possible effect), and (3) patient preference. Every
effort has been made by the committee to make the process
of assigning the strength of the particular recommendation
as transparent as possible. By the GRADE system, the
strength of the recommendation or the extent to which
one can be conﬁdent that adherence to the recommenda-
tion will do more good than harm was divided into [1]
strong (we recommend) and [2] weak (we suggest), with
[1] favoring beneﬁt over harm and [2] with beneﬁts
closely balanced by the risk. The “quality of evidence” or
the extent to which conﬁdence in an estimate of effect is
sufﬁcient to support a particular recommendation was
graded [A], [B], or [C] by standard evidence-based meth-
odologic criteria. It is well recognized that there may not
be studies of the highest evidentiary value for the diagnosis
and management of VLUs. When there are no comparable
alternatives to a recommendation or evidence is lacking,
the Venous Ulcer Guidelines Committee has relied on
case series supplemented by the best opinion of a panel
of experts, and the recommendation was labeled [BESTPRACTICE]. Such recommendations are not graded
but deemed by the guideline developers to be necessary
to provide a comprehensive guideline that encompasses
all the details needed for providing care for patients with
venous ulcers.34 In each section and in the comments to
each speciﬁc recommendation, we have attempted to
clearly link the recommendation to the evidence and its
quality and to point out where consensus techniques
have been used. Independent review of GRADE assign-
ments made by the Venous Ulcer Guidelines Committee
was also performed by the Knowledge and Evaluations
Research Unit at the Mayo Clinic (Rochester, Minn) to
corroborate proper strength of evidence and quality of ev-
idence for each guideline.
The ﬁnal document was reviewed by the chairman and
vice chairman of the Venous Ulcer Guidelines Committee
and remitted to the entire committee for concurrence.
Additional independent review was obtained from selected
reviewers representing multiple medical specialties vested in
venous ulcer management. The ﬁnal document was then
reviewed and approved by the SVS Document Oversight
Committee and approved by the Executive Committees
of the SVS and AVF.
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We suggest use of a standard deﬁnition of venous
ulcer as an open skin lesion of the leg or foot that
occurs in an area affected by venous hypertension.
[BEST PRACTICE]
Guideline 2.1: Venous Anatomy Nomenclature
We recommend use of the International Consensus
Committee on Venous Anatomical Terminology for
standardized venous anatomy nomenclature. [BEST
PRACTICE]
Guideline 2.2: Venous Leg Ulcer Pathophysiology
We recommend a basic practical knowledge of
venous physiology and venous leg ulcer pathophysi-
ology for all practitioners caring for venous leg ulcers.
[BEST PRACTICE]Inherent in composing a set of guidelines for VLU is
agreeing on a common deﬁnition of VLU. Current deﬁni-
tions for VLU vary, as exempliﬁed by the following:
d THE AVF CONSENSUS STATEMENT: Venous ul-
cer is deﬁned as a full-thickness defect of skin, most frequently
in ankle region, that fails to heal spontaneously and is sus-
tained by CVD (duplex studies).35
d SCOTTISH GUIDELINE DEFINITION: Chronic
venous leg ulcer is deﬁned as an open lesion between the
knee and the ankle joint that remains unhealed for at least
four weeks and occurs in the presence of venous disease.
Studies reviewed in this guideline included patients with
venous leg ulcers, irrespective of the method of diagnosis of
venous reﬂux.36
d FRENCH HEALTHCARE SYSTEM GUIDE-
LINES: A pure venous ulcer is deﬁned, by professional
agreement, as a leg lesion, which has not healed within
a month (except in cases of recurrent ulcers when a diag-
nosis can be made in less than a month); with a pathophys-
iology due to ambulatory venous hypertension, which may
be secondary to: reﬂux in superﬁcial, perforating or deep
veins, and/or obstruction of the deep veins, and/or calf
muscle pump dysfunction; where there is no arterial
involvement.37
For the purpose of this Guideline document, we
recommend the following deﬁnition of VLU: A venous
ulcer is an open skin lesion of the leg or foot that occurs
in an area affected by venous hypertension. Venous hy-
pertension is the result of reﬂux or obstruction. This
may occur as a focal phenomenon in the distal extremity
or as a central mechanism, as in iliocaval obstruction or
elevated inferior vena cava pressure from advanced truncal
obesity. The mere existence of either reﬂux or obstruction
does not appear to be the full cause of venous ulcers, with
additional biochemical factors due to activation of the in-
ﬂammatory cascade, which may act as the inciting factor
for appearance of the actual ulcer. Identiﬁcation of these
additional factors awaits further advances in the basic
sciences.
At the clinical level, venous ulcers occur as “pure”
venous causes, when there is directed axial great saphe-
nous vein reﬂux or incompetent perforator reﬂux directly
into the ulcer bed, or as “mixed” venous plus other
causes, as in cases in which arterial ischemia, scarred tis-
sue of the gaiter area, hypersensitive skin, lymphedema,
autoimmune disease, local trauma, infection, and other
processes coexist with the venous hypertension. Themixed ulcers often have a different rate of healing and
require additional treatment beyond the appropriate
venous measures for healing to occur and recurrence to
be prevented. The importance of these diagnoses is that
analysis of healing times and effectiveness of surgical
treatment of the venous component requires separation
of pure venous from mixed ulcers to learn whether treat-
ment of the venous component contributes to faster ulcer
healing and early intervention is favored over delayed
treatment.VENOUS ANATOMY AND PATHOPHYSIOLOGYThe deep veins of the lower limbs are located in the
deep compartment of the leg bound by the muscle fascia
and accompany the main arteries of the leg and pelvis. Su-
perﬁcial veins of the lower limbs are those located between
the deep fascia covering the muscles of the limb and the
skin and primarily included the saphenous system. Perfo-
rating veins pass through the deep muscle fascia and con-
nect the superﬁcial to the deep venous system.
Communicating veins connect veins within the same
system.
Whereas there is general agreement that veins of the
lower extremities be divided into superﬁcial, deep, and
perforating venous systems, there have been deﬁciencies
in the past in nomenclature for speciﬁc veins in the leg
within each system. In response to variability in
anatomic terminology used for venous anatomy, stan-
dard anatomic venous terminology has been developed
and adopted. For practitioners caring for patients with
VLUs, correct standardized venous nomenclature
should be used as deﬁned by the 2002 International
Consensus Committee on Venous Anatomical Termi-
nology and updated in 2005 as shown in Table II and
Table III.38,39Chronic venous disease (CVD) is a debilitating condi-
tion that affects millions of individuals worldwide. The
condition can result in varicose veins or advance to severe
skin changes and VLU. Both reﬂux and obstruction ac-
count for the pathophysiologic mechanism of CVD;
Table II. The International Consensus Committee on Venous Anatomical Terminology for standardized venous
anatomy nomenclature of the leg
Superﬁcial venous system Deep venous system Perforating venous system
Superﬁcial inguinal veins
External pudendal vein
Superﬁcial circumﬂex iliac vein
Superﬁcial epigastric vein
Superﬁcial dorsal vein (clitoris/penis)
Anterior labial veins
Anterior scrotal veins
Great saphenous vein
Saphenofemoral junction
Terminal valve
Preterminal valve
Anterior accessory great saphenous vein
Posterior accessory great saphenous vein
Superﬁcial accessory great saphenous vein
Anterior thigh circumﬂex vein
Posterior thigh circumﬂex vein
Small saphenous vein
Saphenopopliteal junction
Terminal valve
Preterminal valve
Cranial extension of small saphenous vein
Superﬁcial accessory small saphenous vein
Intersaphenous veins
Lateral venous system
Dorsal venous network of the foot
Dorsal venous arch of the foot
Superﬁcial metatarsal veins (dorsal/plantar)
Plantar venous subcutaneous network
Superﬁcial digital veins (dorsal/plantar)
Lateral marginal vein
Medial marginal vein
Common femoral vein
Femoral vein
Deep femoral vein
Medial circumﬂex femoral vein
Lateral circumﬂex femoral vein
Deep femoral communicating veins
Sciatic vein
Popliteal vein
Genicular venous plexus
Anterior tibial veins
Posterior tibial veins
Fibular or peroneal veins
Sural veins
Soleal veins
Gastrocnemius veins
Medial
Lateral
Intergemellar
Medial plantar veins
Lateral plantar veins
Deep plantar venous arch
Deep metatarsal veins (plantar/dorsal)
Deep digital veins (plantar/dorsal)
Pedal vein
Gluteal perforators
Superior gluteal
Midgluteal
Lower gluteal
Thigh perforators
Medial thigh
Femoral canal
Inguinal
Anterior thigh
Lateral thigh
Posterior thigh
Posteromedial
Sciatic
Posterolateral
Pudendal
Knee perforators
Medial knee
Suprapatellar
Lateral knee
Infrapatellar
Popliteal fossa
Leg (calf) perforators
Medial leg
Paratibial
Posterior tibial
Anterior leg
Lateral leg
Posterior leg
Medial gastrocnemius
Lateral gastrocnemius
Intergemellar
Para-achillean
Ankle perforators
Medial ankle
Anterior ankle
Lateral ankle
Foot perforators
Dorsal foot
Medial foot
Lateral foot
Plantar foot
Modiﬁed from Caggiati A, Bergan JJ, Gloviczki P, Eklof B, Allegra C, Partsch H. Nomenclature of the veins of the lower limb: Extensions, reﬁnements, and
clinical application J Vasc Surg 2005;41:719-24.
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higher prevalence in patients presenting with the different
stages of CVD, which might also include venous ulcers.
However, obstruction from secondary venous disease
and valvular reﬂux are associated with a much more rapid
progression of disease and a higher rate of progression to
venous ulceration.40-44 Whether reﬂux or obstruction is
the cause of the patient’s clinical presentation and symp-
toms is unclear; both conditions lead to increased ambu-
latory venous pressure. The fundamental basis for CVD
and venous ulceration is inﬂammation within the venous
circulation that is subjected to increased hydrostatic pres-
sure resulting in increased ambulatory venous pressure.45
The inﬂammation involves leukocytes (in particularmacrophages and monocytes), inﬂammatory modulators
and chemokines, cytokine expression, growth factors,
metalloproteinase activity, and many regulatory pathways
that perpetuate inﬂammation.46-48
The pathophysiologic process of primary venous
disease is a complex entity with multifaceted stages
leading to the dilated tortuous, valve-insufﬁcient vari-
cose veins, venous hypertension, and the associated
clinical manifestations seen with CVD. The pathophys-
iologic mechanism of secondary venous disease involves
inﬂammation, thrombosis, recanalization resulting in
venous wall damage and dilation, and valve insufﬁ-
ciency. The clinical picture is that of the post-
thrombotic syndrome (PTS) and can comprise pain,
Table III. The International Consensus Committee on
Venous Anatomical Terminology for standardized venous
anatomy nomenclature of the pelvis
Main collector Draining veins
Plexus and peripheral
veins
Inferior vena
cava
Ovarian/testicular veins Pampiniform plexus
Common iliac
vein
Median sacral vein
Iliolumbar vein
Internal iliac (hypogastric)
External iliac
Sacral venous plexus
Inferior
mesenteric
vein
Superior rectal vein
Middle rectal vein
Inferior rectal vein
Superior gluteal vein
Inferior gluteal vein
Lateral sacral vein
External rectal plexus
Internal rectal plexus
Internal iliac
vein
Internal pudendal vein
Obturator veins
Vesical veins
Uterine veins
Vaginal veins
Deep perineal veins
Superﬁcial perineal
veins
Deep dorsal veins of
clitoris/penis
Deep veins of clitoris/
penis
Urethral bulb veins
Pudendal plexus
Vesical/prostatic
plexus
Uterine plexus
Vein of the broad
ligament
Vaginal plexus
External iliac
vein
Pubic veins (accessory
obturator veins)
Sovrapubic veins
Inferior epigastric vein
Deep circumﬂex iliac
vein
Modiﬁed from Caggiati A, Bergan JJ, Gloviczki P, Eklof B, Allegra C,
Partsch H. Nomenclature of the veins of the lower limb: Extensions, re-
ﬁnements, and clinical application J Vasc Surg 2005;41:719-24.
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tion is a risk for development of PTS. When the mean
lysis time was reduced, the risk of reﬂux was signiﬁ-
cantly reduced, especially in the femoral, popliteal,
and deep femoral veins, a critical parameter for preser-
ving valve function.49 From a basic science perspective,
venous thrombosis and resolution involve important
factors including microparticles, P-selectin, coagulation
cascade and ﬁbrin, macrophages, adhesion molecules,
vascular endothelial growth factor, matrix metallopro-
teinases (MMPs), inﬂammatory cytokines and interleu-
kins, chemokines, plasmin, and plasminogen activators
and inhibitors, all of which affect the vein wall and its
compliance, including valvular function.50,51
Several epidemiologic studies have assessed the associ-
ated risk factors. Certainly, genetic and environmental
factors inﬂuence the predisposition to and perpetuation
of primary venous disease. Some important observationsare a family history, female gender, pregnancy, estrogen,
prolonged standing, sitting postures, and obesity. Genetic
conditions, such as Klippel-Trénaunay syndrome, cerebral
autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL) and FOXC2 gene
mutations, desmulin dysregulation, and Ehlers-Danlos
syndrome, display early onset of varicose veins.46,52 How-
ever, most individuals with primary venous disease do not
have these genetic conditions, and a speciﬁc gene leading
to primary venous disease and varicose veins has not been
identiﬁed, although it appears that the trait is autosomal
dominant with variable penetrance.52,53 Further studies
have focused on genetic polymorphism in populations
with CVD in the development and healing potential of
venous ulcers.54 Hemochromatosis C282Y (HFE) gene
mutation and certain factor XIII V34L gene variants
have been demonstrated in patients with CVD and vari-
cose veins and may have long-term implications for
increased risk of the more severe forms of CVD as well
as the size of venous ulcers.55,56 Factor XIII is an impor-
tant cross-linking protein that plays a key role during ul-
cer healing.57 HFE and factor XIII genes were also
evaluated in predicting VLU healing after superﬁcial
venous surgery in patients with CVD. It was demon-
strated that speciﬁc factor XIII genotypes had favorable
ulcer healing rates, whereas the HFE gene mutation,
despite its importance in venous ulcer risk, had no inﬂu-
ence on healing time.58
It is clear from biochemical, immunohistochemical,
and functional studies that both the vein wall and the
valve are involved in the primary events leading to venous
disease. Whether the vein wall changes precede valve
insufﬁciency or the valve insufﬁciency causes wall disten-
tion and wall changes is less clear.46 More important, ev-
idence demonstrates that both vein wall and vein valve
are pathologically altered to cause primary venous dis-
ease. The perturbation in the microcirculation is a critical
component in the pathophysiologic process of CVD. The
endothelium is a key regulator of vascular tone, hemosta-
sis, and coagulation. Injury, infection, immune diseases,
diabetes, genetic predisposition, environmental factors,
smoking, and atherosclerosis all have an adverse effect
on the endothelium, which in turn must compensate to
prevent further injury and maintain integrity of the
vascular wall. In CVD, the sine qua non is persistent
elevated ambulatory venous pressure. The effect on the
microcirculation begins with altered shear stress on the
endothelial cells, causing endothelial cells to release vaso-
active agents and to express E-selectin, inﬂammatory
molecules, chemokines, and prothrombotic precur-
sors.59,60 Mechanical forces, low shear stress, and stretch
are sensed by the endothelial cells through intercellular
adhesion molecule 1 (ICAM-1, CD54) and the mecha-
nosensitive transient receptor potential vanilloid channels
that are present in the endothelium.60,61 It is well known
that patients with CVD have increased expression of
ICAM-1, which is expressed on endothelial cells and
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endothelial transmigration, setting up an inﬂammatory
cascade.62,63 Initiating events likely involve altered shear
stress and mechanical stress forces on the endothelium
and its glycocalyx (a glycosaminoglycan on the surface
of endothelial cells); perturbations in nitric oxide produc-
tion, in vasoactive substance release, and in the ex-
pression of monocyte chemoattractant protein 1,
macrophage inﬂammatory protein 1b, vascular cell adhe-
sion molecule 1 (VCAM-1, CD106), L-selectins and E-
selectins, and ICAM-1, with recruitment of leukocytes
leading to leukocyte transmigration into the vein wall
and valve, set up an inﬂammatory cascade and produc-
tion of several cytokines (transforming growth factor
[TGF]-b1, tumor necrosis factor [TNF]-a, interleukin-
1) and increased expression of MMPs.48,60 In addition,
the endothelial glycocalyx is an important structure that
prevents leukocyte adhesion, inﬂammation, and throm-
bosis. However, altered shear stress and mechanical
forces on the vein wall cause leukocyte adhesion, and
inﬂammation leads to injury and loss of the glycoca-
lyx.64,65 A key component of inﬂammation and in the
VLU is the expression of MMP and cytokines, which
have signiﬁcant effects on the vein wall and venous valve,
the endothelium, and probably the glycocalyx and sur-
rounding tissues, including destruction of the dermis
with eventual skin changes and ulcer formation.48
MMPs can be released as a result of mechanical stretch
(and hence during conditions of venous hypertension)
and have signiﬁcant effects on the endothelium, venous
smooth muscle, and adventitia.66,67 MMPs have been
demonstrated in rat venous tissue to cause venous dila-
tion by several mechanisms, including hyperpolarization
and inhibition of extracellular calcium mobilization,
which are tightly regulated by hypoxia-inducible factor
(HIF).68-70 In a study evaluating varicose veins in CVD
patients, it was determined that HIF-1a and HIF-2a
transcriptional factors were overexpressed compared
with control nonvaricose veins, suggesting that the HIF
pathway may be associated with several pathophysiologic
changes in the venous wall leading to venous hyperten-
sion and that hypoxia may be a feature contributing to
the pathogenesis of varicose veins.70
MMPs have been found to be present in high quan-
tities in VLUs and the associated wound ﬂuid, and there
is a correlation of increased expression of proteinase ac-
tivity with poor healing. The regulation of MMP produc-
tion and function, although not fully understood, is likely
to be linked to cytokines, urokinase plasminogen acti-
vator, EMMPRIN (extracellular MMP inducer
CD147), platelet-derived growth factor AA, and
mitogen-activated protein kinase pathways.71-82 Impor-
tantly, the mitogen-activated protein kinase pathways in
venous ulcer ﬁbroblast have been demonstrated to over-
express P38, a negative modulator of cell proliferation
causing growth arrest, which can also be upregulated
with the cytokines TNF-a and interleukin-1. The expres-
sion of P38 can be suppressed, leading to ﬁbroblastgrowth, by treatment with ﬁbroblast growth factor.48,62
Cytokines have important roles at different stages of
CVD, beginning with inﬂammation, with expression in
the interstitial space and in the venous ulcer wound
bed.48 In a nonrandomized evaluation of various cyto-
kine levels and venous ulcer healing in patients undergo-
ing compression therapy, it was determined that
untreated ulcers typically display high levels of proinﬂam-
matory cytokines, including several interleukins, TNF-a,
and interferon-g. After 4 weeks of compression therapy,
the levels of proinﬂammatory cytokines decreased signif-
icantly and the wounds began to heal. After compression,
levels of TGF-b1 increased signiﬁcantly as the ulcers
improved. When speciﬁc cytokine levels were related to
the percentage of healing, it was found that those with
higher levels of proinﬂammatory cytokines including
interleukin-1 and interferon-g healed signiﬁcantly better
than those with lower levels of these cytokines before
compression.83 As a result of venous hypertension,
inﬂammation, and remodeling, a key feature takes place
in the postcapillary venule where the ﬁbrin cuff, a com-
plex process involving ﬁbrin and collagen deposition, is
formed. The result is a major abnormality in dermal
microcirculation with many components forming the
postcapillary cuff, including collagen I and III, ﬁbro-
nectin, vitronectin, laminin, tenascin, ﬁbrin, TGF-b1,
and a2-macroglobulin.
48,84 Although the exact mecha-
nisms and reasons for development of the ﬁbrin cuff are
unknown, the chemical and structural changes in the
postcapillary venule are thought to be in response to
changes in shear stress and elevated venous pressures,
which probably lead to progressive dermal changes and
ulceration. Structural proteins have been analyzed in vari-
cose veins from patients with CVD, with the important
ﬁnding that overall collagen is increased and both elastin
and laminin are decreased.85 When the collagen was
examined in smooth muscle from varicose veins, the
consistent ﬁnding was that there was a signiﬁcant
decrease of collagen type III and increased type I, and
the same biochemical proﬁle was also observed in the
dermal ﬁbroblasts from varicose vein patients.85,86 These
ﬁndings indicate a systemic condition with strong genetic
inﬂuences, and because collagen I confers rigidity
whereas collagen III is involved in the extensibility of a
tissue, modiﬁcation of the collagen I/III ratio might
contribute to the weakness and the decreased elasticity
of varicose veins. Interestingly, the transcription of
collagen III is normal in smooth muscle cells from vari-
cose veins and the activity of MMP-3 is increased, leading
to post-translational modiﬁcation of collagen type III;
these events are reversible when MMP-3 is inhibited
in vitro.87 MMPs are an important step in the develop-
ment of primary venous disease; their implications are
in early events affecting endotheliumesmooth muscle in-
teractions and venodilation as well as in late events, with
extracellular matrix degradation, structural vein wall
changes and ﬁbrosis, and tissue damage leading to venous
ulceration.
Guideline 3.1: Clinical Evaluation
We recommend that for all patients with suspected
leg ulcers ﬁtting the deﬁnition of venous leg ulcer, clin-
ical evaluation for evidence of chronic venous disease be
performed. [BEST PRACTICE]
Guideline 3.2: Nonvenous Causes of Leg Ulcers
We recommend identiﬁcation of medical conditions
that affect ulcer healing and other nonvenous causes of
ulcers. [BEST PRACTICE]
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both in control specimens and in patients with
CVD.88 The interesting aspect of that study is a system
of sequentially smaller generations of tributaries leading
to small venous networks, with competent and incom-
petent microvalves. The regions are divided into six gen-
erations before reaching the small venous network. In
regions where incompetence existed in microvalves out
to the third-generation tributary (the boundary), the
resin (resin injected by retrograde corrosion casting)
was able to penetrate deeper into the microvenous net-
works of the dermis. In limbs with varicose veins and
venous ulcers, reﬂux into the small venous networks
and capillary loops was more extensive with more dense
networks and greater tortuosity. In addition to superﬁ-
cial axial saphenous vein insufﬁciency, microvalve insuf-
ﬁciency also existed, and once it compromised the
third-generation set of microvalves, there was a greater
risks for the development of dermal venous ulceration.
These ﬁndings may help explain why some patients
with long-standing varicose veins do not develop venous
ulcers because the microvalves may be intact at the
third-generation network, preventing clinical deteriora-
tion. In addition, these ﬁndings may explain why skin
changes consistent with venous disease (hyperpigmenta-
tion and even small skin ulceration) are seen clinically in
patients with normal ﬁndings on duplex ultrasound of
the superﬁcial, deep, and perforator venous systems.
Further research on the factors responsible for initiating
the altered shear stress and stretch on vein walls will
make it possible to have speciﬁc pharmaceutical targets
to restore the integrity of the microcirculation, to treat
the spectrum of CVD, and to prevent progression of
VLUs.
Metabolic abnormalities may be critical to venous
dysfunction and lead to disease. Metabonomics is the
study of metabolism in biologic systems in response to
pathophysiologic stimuli and genetic modiﬁcations. In
patients with varicose veins, there are signiﬁcant differ-
ences in three important metabolic products; creatine,
lactate, and myoinositol metabolites are increased and
amounts of lipid metabolites are lower compared with
nonvaricose control veins.89 Analysis of the cellular
metabolism in varicose veins, with signature end prod-
ucts, reﬂects the metabolism of the tissue and provides
key information to the disease processes. Further
research in this exciting ﬁeld is necessary to have a bet-
ter understanding of the processes leading to CVD and
to determine whether patients with venous ulcers have
certain characteristic metabolic proﬁles that will allow
improved targeted therapy in both the prevention and
active treatment of CVD and VLUs. Another potential
mechanism for the development of CVD and VLUs is
hypoxia in the dermis and apoptosis of the vein wall;
however, studies evaluating these pathophysiologic al-
terations are more likely to be simple associations,
with signiﬁcant variability in results and therefore
inconclusive.90,91CLINICAL EVALUATIONFor a leg ulcer to be classiﬁed as a VLU, there needs to
be clinical manifestations consistent with CVD. Clinical
evaluation should differentiate primary, secondary, or
congenital venous problems and establish presence or
absence of venous reﬂux, obstruction, or both. A thorough
medical history should be performed to identify symptoms
potentially related to venous disease, including extremity
pain, burning aching, throbbing, cramps, heaviness, itch-
ing, tiredness, fatigue, and restless legs. Venous symptoms
are usually exacerbated by limb dependency and relieved by
rest or elevation. Medical history should also include risk
factor assessment for venous disease, including age, body
mass index, prior venous thromboembolism, family history
of venous thromboembolism, family history of varicose
veins, episodes of superﬁcial thrombophlebitis, sponta-
neous venous rupture, prior use of compression therapy,
prior venous operative interventions, use of venotonic
medications, presence of other systemic diseases associated
with leg wounds, and other possible associated medical fac-
tors that may contribute to nonhealing leg wounds. Phys-
ical examination for signs of venous disease should include
inspection for telangiectasia, varicose veins, edema, chronic
venous skin changes (skin discoloration, inﬂammation,
eczema, hyperpigmentation, malleolar ﬂair, corona phle-
bectatica, atrophie blanche, lipodermatosclerosis), healed
ulcer, and active ulcer; palpation for varicosity, palpable
venous cord, tenderness, induration, edema, and pulses;
auscultation for bruit and reﬂux; and evaluation of ankle
mobility.92-96Differentiation of venous from nonvenous leg ulcers
is important before initiation of therapy. In a deﬁned
Swedish population, prevalence of active leg ulcers was
0.31%, with 54% classiﬁed as venous and 46% nonve-
nous.97 In a population-based study from Germany
including 31,619 patients, venous reﬂux was the causative
factor in 47.6%, arterial insufﬁciency in 14.5%, and com-
bined arterial and venous reﬂux in 17.6%. Rarer causes
included vasculitis (5.1%), exogenous factors (3.8%), pyo-
derma gangrenosum (3.0%), infection (1.4%), neoplasia
Table IV. Differential diagnosis for leg ulcers
Vascular disease
- Venous: post-thrombotic syndrome, varicose veins, chronic venous reﬂux
- Arterial: peripheral arterial occlusive disease, hypertension, arteriovenous ﬁstulas, arterial thrombosis, embolism, dysplasia,
thromboangiitis obliterans, aneurysm
- Lymphatic: lymphedema
- Microangiopathy: diabetes mellitus, livedoid vasculopathy
- Vasculitis
- Hypertensive arteriolopathy
Neuropathic
- Peripheral neuropathy: diabetes mellitus, alcohol, medication, hereditary
- Central neuropathy: tabes dorsalis, myelodysplasia, syringomyelia, spina biﬁda, poliomyelitis, multiple sclerosis
Metabolic
- Diabetes mellitus, gout, prolidase deﬁciency, Gaucher disease, amyloidosis, calciphylaxis, porphyria, hyperhomocysteinemia
Hematologic
- Sickle cell anemia, thalassemia, polycythemia vera, leukemia, thrombocythemia, lymphoma, myeloplastic disorders, disorders of coagu-
lation factors (factors I-XIII), coagulation inhibitors (antithrombin III, activated protein C resistance, protein C and S), or ﬁbrinolysis
factors (tissue plasminogen activator, plasminogen activator inhibitor, plasmin)
Autoimmune
- Rheumatoid arthritis, leukocytoclastic vasculitis, polyarteritis nodosa, Wegener granulomatosis, Churg-Strauss syndrome, systemic lupus
erythematosus, Sjögren syndrome, scleroderma, Behçet disease, cryoglobulinemia
Exogenous
- Heat, cold, pressure, ionizing radiation, chemical, allergens, trauma
Neoplasia
- Basal cell carcinoma, squamous cell carcinoma (Marjolin ulcer), malignant melanoma, angiosarcoma, cutaneous lymphoma, papilloma-
tosis cutis carcinoides, keratoacanthoma
Infection
- Bacterial: furuncles, ecthyma, mycobacterioses, syphilis, erysipelas, anthrax, diphtheria, chronic vegetative pyodermia, tropical ulcer
- Viral: herpes, variola virus, cytomegaly
- Fungal: sporotrichosis, histoplasmosis, blastomycosis, coccidioidomycosis
- Protozoal: leishmaniasis
Medication
- Hydroxyurea, leﬂunomide, methotrexate, halogens, coumarin, vaccinations, ergotamine, inﬁltration cytostatic agents
Genetic defect
- Klinefelter syndrome, Felty syndrome, TAP1 mutation, leukocyte adhesion deﬁciency, inherited hypercoagulable factors
Skin disorder
- Pyoderma gangrenosum, necrobiosis lipoidica, sarcoidosis, perforating dermatosis, Langerhans cell histiocytosis, papulosis maligna
atrophicans, bullous skin diseases
Modiﬁed from Dissemond J, Korber A, Grabbe S. Differential diagnosis of leg ulcers. J Dtsch Dermatol Ges 2006;4:627-34.
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Other medical conditions that can cause leg ulcers and
affect ulcer healing should also be identiﬁed. Differential
diagnosis of possible causes for leg ulcers is shown in
Table IV.99-101Guideline 3.4: Wound Culture
We suggest against routine culture of venous leg ul-
cers and only to obtain wound culture specimens when
clinical evidence of infection is present. [GRADE - 2;
LEVEL OF EVIDENCE - C]
Guideline 3.3: Wound Documentation
We recommend serial venous leg ulcer wound mea-
surement and documentation. [BEST PRACTICE]Serial VLU wound measurement and documentation
are important to determine baseline markers and effect of
subsequent treatment measures on healing parameters.
Documentation should include number and position of
ulcers on the leg. Wound measurements should be
made for each VLU, including area, perimeter, and
depth, with additional descriptors of wound edge param-
eters, wound base quality, drainage, and infection.Adjuncts for standardization of ulcer documentation,
including wound planimetry, digital photography, and
digital planimetry software, are recommended.102-113There is no evidence to support routine microbiology
surface cultures of VLU in the absence of clinical signs of
infection as these wounds are usually colonized by multiple
micro-organisms. If there are no clinical signs of infection
and the wound is responding to treatment, there is no indi-
cation to culture the wound.114-118
For patients with VLUs who develop associated clinical
signs of infection, such as fever, leukocytosis, worsening
Guideline 3.7: Arterial Testing
We recommend arterial pulse examination and
measurement of ankle-brachial index on all patients
with venous leg ulcer. [GRADE - 1; LEVEL OF
EVIDENCE - B]
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colored friable granulation tissue, bioﬁlm, tissue necrosis,
or ulcer progression, microbiologic cultures are recom-
mended. Microbiology cultures can be obtained from
wound surface or wound drainage by validated quantita-
tive bacteriology swab methods with reproducible reli-
ability compared with deep wound tissue biopsy and
culture. Molecular techniques using polymerase chain re-
action analysis may improve pathogen identiﬁcation over
standard swab culture methods.119,120 Deep wound tissue
cultures should be reserved for wounds colonized with
multiple micro-organisms when the bacterial pathogen is
not clear from surface cultures, for bioﬁlm infections, or
for recurrent or persistent infection despite appropriate
antimicrobial therapy.121-125Guideline 3.5: Wound Biopsy
We recommend wound biopsy for leg ulcers that do
not improve with standard wound and compression
therapy after 4 to 6 weeks of treatment and for all ul-
cers with atypical features. [GRADE - 1; LEVEL OF
EVIDENCE - C]When VLUs do not respond to standard wound and
compression therapy, contributing factors should be consid-
ered, including infection and possible misdiagnosis. Whereas
evidence does not support an absolute time frame, most ev-
idence and clinical practice guidelines suggest tissue biopsy
considerations within 4 to 6 weeks of nonresponsiveness
to standard treatment. The biopsy specimen should be ob-
tained from several sites, including the wound edge and cen-
tral provisional matrix. Another consideration for tissue
biopsy independent of time frame is differentiation of other
possible nonvenous causes for leg ulcer. Although malig-
nancy is rare, for any VLU with atypical features, wound tis-
sue biopsy should also be performed.126-128 Although
wound tissue biopsy provides valuable histologic differentia-
tion, additional tissue analysis to include inﬂammatory cyto-
kines and MMPs is still under investigation and does not
have current clinical applicability.83,129,130Guideline 3.6: Laboratory Evaluation
We suggest laboratory evaluation for thrombo-
philia for patients with a history of recurrent venous
thrombosis and chronic recurrent venous leg ulcers.
[GRADE - 2; LEVEL OF EVIDENCE - C]Several studies have shown that patients with VLUs
have an increased prevalence of thrombophilia.131-133 This
association is increased in patients with documented throm-
botic events, family history of thrombotic events, early-onset
VLU before the age of 50 years, and recurrent or recalcitrant
VLUs.134-136 Evidence supports selective laboratory evalua-
tion for thrombophilia in all patients with VLU and a historyof recurrent venous thrombosis and chronic recurrent
VLUs. Laboratory evaluation for thrombophilia should
include testing for inherited hypercoagulable factors (anti-
thrombin deﬁciency, protein C and protein S deﬁciencies),
factor V Leiden (resulting in activated protein C resistance),
prothrombin G20210A, plasminogen activator inhibitor
type 1 mutations, hyperhomocysteinemia, antiphospholipid
antibodies (anticardiolipin and lupus anticoagulant), and
cryoglobulins and cryoagglutinins.Because adequate arterial perfusion is needed for
improved healing, it is important to identify the presence
of underlying peripheral arterial disease (PAD).137,138
Approximately 15% to 25% of patients with VLUs will
have a concomitant PAD component.97,98,139,140 Evalua-
tion of possible risk factors for PAD includes male gender,
age, smoking, hypertension, dyslipidemia, diabetes,
obesity, coexisting cardiovascular disease, stroke, renal
insufﬁciency, hyperhomocysteinemia, and family history
of cardiovascular disease. Symptoms and signs of PAD
include claudication, rest pain, and ischemic ulceration or
necrosis. Key components of the physical examination
include measurement of blood pressure in both arms, car-
diac auscultation, leg examination (changes in color, skin
temperature, muscle atrophy, decreased hair growth, hy-
pertrophied nails), and complete pulse examination (palpa-
tion for aneurysms; auscultation for bruits in carotid, aorta,
or femoral region; palpation of the radial, ulnar, brachial,
carotid, femoral, popliteal, dorsalis pedis, and posterior
tibial artery pulse). Lower extremity Doppler examination
is standard for patients with suspected PAD. Measurement
of ankle-brachial index (ABI) is performed in the supine
position with a sphygmomanometer cuff placed just above
the ankle and a continuous-wave Doppler probe used to
measure the systolic pressure of the posterior tibial and dor-
salis pedis arteries of each leg, which is then normalized to
the higher brachial pressure of either to calculate the ABI for
each leg. ABI is calculated by dividing the systolic ankle pres-
sure by systolic arm pressure. The reproducibility of the ABI
varies, but it is signiﬁcant enough that reporting standards
require a change of 0.15 in an isolated measurement for it
to be considered clinically relevant or>0.10 if it is associated
with a change in clinical status. The typical cutoff point for
diagnosis of PAD is ABI#0.90 at rest, with ABI#0.50 usu-
ally corresponding to critical limb ischemia. In patients with
diabetes, renal insufﬁciency, or other diseases that cause
vascular calciﬁcation, tibial vessels at the ankle become
noncompressible, leading to a false elevation of the ankle
pressure and ABI. In these patients, additional noninvasive
diagnostic testing, such as pulse volume recordings or toe
pressure measurement, should be performed to evaluate
for PAD. For ABI #0.90, referral should be made to a
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comprehensive lower extremity arterial Doppler study, arte-
rial imaging, and possible revascularization consideration
before VLU compression or operative therapy.141Guideline 3.8: Microcirculation Assessment
We suggest against routine microcirculation assess-
ment of venous leg ulcers but suggest selective consid-
eration as an adjunctive assessment for monitoring of
advanced wound therapy. [GRADE - 2; LEVEL OF
EVIDENCE - C]Whereas objective microcirculation assessment by
transcutaneous oxygen, laser Doppler perfusion, and capil-
lary microscopy has shown correlation with healing of
other wounds, there is insufﬁcient evidence showing
beneﬁt for VLUs. Microcirculation assessment may be use-
ful as an adjunct for mixed arterial and VLUs, when there is
concern for adequate microcirculation related to other
medical conditions involving capillary perfusion, or for
monitoring of advanced wound therapy.142-144Guideline 3.9: Venous Duplex Ultrasound
We recommend comprehensive venous duplex ul-
trasound examination of the lower extremity in all pa-
tients with suspected venous leg ulcer. [GRADE - 1 ;
LEVEL OF EVIDENCE - B]
Guideline 3.10: Venous Plethysmography
We suggest selective use of venous plethysmog-
raphy in the evaluation of patients with suspected
venous leg ulcer if venous duplex ultrasound does not
provide deﬁnitive diagnostic information. [GRADE -
2; LEVEL OF EVIDENCE - B]
Guideline 3.11: Venous Imaging
We suggest selective computed tomography venog-
raphy, magnetic resonance venography, contrast
venography, and/or intravascular ultrasound in pa-
tients with suspected venous leg ulceration if additional
advanced venous diagnosis is required for thrombotic
or nonthrombotic iliac vein obstruction or for opera-
tive planning before open or endovenous interventions.
[GRADE - 2; LEVEL OF EVIDENCE - C]For a leg ulcer to be classiﬁed as a VLU, there needs to
be objective documented evidence of venous disease. Ul-
trasound assessment needs to include evaluation for both
obstructive and reﬂux patterns of venous disease. Whereas
continuous-wave Doppler ultrasonography can be used,
comprehensive color ﬂow venous duplex ultrasound
including B-mode gray-scale imaging, pulsed Doppler sam-
pling, and color ﬂow analysis has improved diagnostic accu-
racy and reproducibility and is the preferred ﬁrst-line
diagnostic test for all patients with suspected VLU.145-148
Comprehensive venous duplex ultrasound evaluates for
both venous obstruction/DVT and venous reﬂux and in-
cludes the following components: direct visualization of
deep, superﬁcial, and perforator venous anatomic segments;
compressibility; phasic venous ﬂow with and without
augmentation maneuvers; and documentation of venous
reﬂux with measurement of valve closure time.149,150
Venous obstruction is present when thrombosis is directly
visualized, noncompressibility of vein segment is present,
phasic venous ﬂow is absent with and without augmentation
maneuvers, and extensive collateral vessels are present
around the segment. To identify valvular incompetence, a
portion of the venous duplex ultrasound examination should
be performed in the upright or standing position. Augmen-
tation maneuvers include Valsalva maneuver for common
femoral vein and saphenofemoral junction and use of
manual or cuff compression/release placed distal to the
point of examination for lower extremity veins below the
femoral junction.151,152 Most studies suggest criteria for
valvular incompetence when valve closure time exceeds$1 second for femoral and popliteal veins and $0.5 second
for great saphenous vein, small saphenous vein, tibial veins,
deep femoral vein, and perforating veins.153 However, use
of $0.5 second for all superﬁcial and deep vein segments
can signiﬁcantly improve the reliability of reﬂux detec-
tion.154 Perforator vein is deﬁned as pathologic when direc-
tional ﬂow is from deep to superﬁcial, valve closure time is
$0.5 second, vein diameter exceeds 3.5 mm, and location
of perforator is beneath healed or active VLU.155,156
Venous duplex ultrasound not only provides diagnostic
utility but also will identify patterns of venous disease that
may have therapeutic implications.157,158 Because VLUs
are usually associated with multilevel disease affecting the su-
perﬁcial, deep, and perforating veins, better deﬁning these
variable patterns of venous disease is critically important
before any treatment. Evidence supports that 74% to 93%
of all patients with VLUs will have superﬁcial vein involve-
ment, but superﬁcial venous reﬂux will be isolated in only
17% to 54% of the limbs, the remainder of which will have
either isolated or combined associated deep vein incompe-
tence or obstruction or perforator incompetence.159-161
Additional anatomic patterns of axial reﬂux directed to the
bed of the VLU are important to be deﬁned.162Venous plethysmography (strain-gauge, air, or photople-
thysmography) provides additional venous limb physiologic
parameters regarding global venous reﬂux, outﬂow obstruc-
tion, and calf muscle pump function and has shown good cor-
relation with venous duplex ultrasound.163-168 Some studies
have shown utility for monitoring of venous functional
changes and assessment of physiologic outcome of surgical
treatments.169-172 However, current evidence does not sup-
port a primary role for venous plethysmography as a diagnostic
test for venous disease above venous duplex ultrasound.
Venous plethysmography should be reserved for equivocal
ﬁndings of venous duplex ultrasound examination, for recalci-
trant or recurrent VLU, or if additional venous physiologic
testing is required for diagnostic or therapeutic reasons.Venous outﬂow obstruction has been underappreci-
ated as a cause of venous hypertension and associated
venous disease because of lack of a noninvasive screening
Table V. Basic CEAP classiﬁcation system
Clinical classiﬁcation
C0 No visible or palpable signs of venous disease
C1 Telangiectases or reticular veins
C2 Varicose veins
C3 Edema
C4a Pigmentation and/or eczema
C4b Lipodermatosclerosis and/or atrophie blanche
C5 Healed venous ulcer
C6 Active venous ulcer
CS Symptoms, including ache, pain, tightness, skin irritation,
heaviness, muscle cramps, as well as other
complaints attributable to venous dysfunction
CA Asymptomatic
Etiologic classiﬁcation
Ec Congenital
Ep Primary
Es Secondary (post-thrombotic)
En No venous etiology identiﬁed
Anatomic classiﬁcation
As Superﬁcial veins
Ap Perforator veins
Ad Deep veins
An No venous location identiﬁed
Pathophysiologic classiﬁcation
Pr Reﬂux
Po Obstruction
Pr,o Reﬂux and obstruction
Pn No venous pathophysiology identiﬁable
Modiﬁed from Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Glo-
viczki P, Kistner RL, et al. Revision of the CEAP classiﬁcation for chronic
venous disorders: Consensus statement. J Vasc Surg 2004;40:1248-52.
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duplex ultrasound of the femoral vein may provide indirect
evidence of outﬂow obstruction with monophasic wave-
forms, loss of respiratory variation in the femoral tracing,
or poor augmentation of the signal with distal limb
compression.174 Although the diagnostic accuracy of
duplex ultrasound may be improved by performing direct
duplex ultrasound examination of iliocaval veins, reliable
and reproducible imaging may be limited by body habitus,
intestinal gas, and operator variability.175 Use of venous
plethysmography for identiﬁcation of venous obstruction
has also been described, but venous plethysmography is
not widely available, limiting its usefulness as a screening
modality.176
For improved diagnostic accuracy, patients with VLU
and suspected thrombotic or nonthrombotic venous
obstruction should undergo additional contrast imaging
with computed tomography venography (CTV) or mag-
netic resonance venography (MRV).177-179 In one study,
37% of patients with prior healed or active VLUs had evi-
dence of iliocaval venous obstruction >50% and 23%
>80% on CTV or MRV, with a higher propensity in
women, with prior history of DVT, and with evidence of
deep venous reﬂux on duplex ultrasound.180
Whereas screening CTV and MRV may provide addi-
tional information about potential venous outﬂow obstruc-
tion, diagnosis should be conﬁrmed by contrast
venography and intravascular ultrasound. Imaging with
intravascular ultrasound with cross-sectional views of the
vein and adjacent structures has high diagnostic accuracy
in determining presence of iliocaval thrombus burden or
iliocaval compression due to May-Thurner syndrome or
other adjacent structures, which may have bearing on addi-
tional therapeutic options.181-183Guideline 3.12: Venous Disease Classiﬁcation
We recommend that all patients with venous leg ul-
cer be classiﬁed on the basis of venous disease classiﬁca-
tion assessment, including clinical CEAP, revised
Venous Clinical Severity Score, and venous diseasee
speciﬁc quality of life assessment. [BEST PRACTICE]Accurate classiﬁcation of venous disease is critically
important for standardization of venous disease severity
and assessment of treatment effectiveness. Classiﬁcation
systems for reporting of venous disease severity have been
in existence for many years, with recent emphasis on
both patient- and physician-generated assessment tools
that can be used to follow clinically deﬁned end points
and changes over time.
The Clinical class, Etiology, Anatomy, and Pathophysi-
ology (CEAP) classiﬁcation, introduced in 1994 and revised
in 2004, forms the basis for CVD documentation, and should
be used for all patients with VLUs.184-186 The basic CEAP
classiﬁcation (Table V) is a simpliﬁed version of the more
comprehensive CEAP and is recommended for clinical prac-
tice, with the more comprehensive CEAP reserved for
research purposes. Whereas the CEAP classiﬁcation systemis useful to classify stages of venous disease, its components
have been recognized to be relatively static and insufﬁcient
for determining changes in venous disease severity. For
example, a patient presenting with an active VLU will be clin-
ical CEAPe6 but when the ulcer heals can improve at best
only to clinical CEAPe5. Despite this shortcoming, there
has been general acceptance and wide dissemination of
CEAP for both clinical and research purposes, making
CEAP an essential component of venous disease classiﬁcation.
In an effort to improve standardized outcome assess-
ment of venous disease with gradable elements that can
change in response to treatment, the Venous Clinical
Severity Score (VCSS) was introduced in 2000 and revised
in 2010 (Table VI). The VCSS system includes 10 clinical
descriptors (pain, varicose veins, venous edema, skin pigmen-
tation, inﬂammation, induration, number of active ulcers,
duration of active ulceration, size of ulcer, and compressive
therapy use), scored from 0 to 3 (total possible score, 30),
that may be used to assess changes in response to therapy.
VCSS has been shown to have minimal intraobserver and
interobserver variability, and validation with objective venous
parameters has been shown in a few studies.187-192 The more
recent revised VCSS (rVCSS) should be determined on
initial evaluation and then at serial intervals for assessment
of clinical outcome after nonoperative and operative treat-
ment of VLUs and has been shown to be a better tool for
assessing response to treatement.192,193 VCSS $8 indicates
a patient with severe disease at risk for progression and war-
rants additional diagnostics or treatment.194
Table VI. Revised Venous Clinical Severity Scoring (VCSS) system
None: 0 Mild: 1 Moderate: 2 Severe: 3
Pain or other discomfort (ie,
aching, heaviness, fatigue,
soreness, burning)
Occasional pain or other
discomfort (ie, not
restricting regular daily
activities)
Daily pain or other discomfort
(ie, interfering with but not
preventing regular daily
activities)
Daily pain or discomfort
(ie, limits most regular
daily activities)
Presumes venous origin
Varicose veins
“Varicose” veins must be
$3 mm in diameter to
qualify in the standing
position
Few: scattered (ie, isolated
branch varicosities or
clusters)
Also includes corona
phlebectatica (ankle ﬂare)
Conﬁned to calf or thigh Involves calf and thigh
Venous edema
Presumes venous origin Limited to foot and ankle
area
Extends above ankle but
below knee
Extends to knee and above
Skin pigmentation
Presumes venous origin None
or focal
Limited to perimalleolar area Diffuse over lower third
of calf
Wider distribution above
lower third of calf
Does not include focal
pigmentation over
varicose veins or
pigmentation due to
other chronic diseases
Inﬂammation
More than just recent
pigmentation (ie,
erythema, cellulitis,
venous eczema,
dermatitis)
Limited to perimalleolar area Diffuse over lower third
of calf
Wider distribution above
lower third of calf
Induration
Presumes venous origin of
secondary skin and
subcutaneous changes
(ie, chronic edema with
ﬁbrosis, hypodermitis).
Includes white atrophy
and lipodermatoselerosis
Limited to perimalleolar area Diffuse over lower third
of calf
Wider distribution above
lower third of calf
Active ulcer number 0 1 2 $3
Active ulcer duration (longest
active)
N/A <3 mo >3 mo but <1 y Not healed for >1 y
Active ulcer size (largest
active)
N/A Diameter <2 cm Diameter 2-6 cm Diameter >6 cm
Use of compression therapy 0 1 2 3
Not used Intermittent use of stockings Wears stockings most days Full compliance: stockings
Modiﬁed from Vasquez MA, Rabe E, McLafferty RB, Shortell CK, Marston WA, Gillespie D, et al. Revision of the venous clinical severity score:
Venous outcomes consensus statement: Special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg
2010;52:1387-96.
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VLUs, additional classiﬁcation of PTS should be performed
for all patients with prior DVT. Several PTS scoring sys-
tems have been used both to diagnose and to classify
PTS severity, including those described by Villalta,195 Gins-
berg,196 Brandjes,197 and Widmer.198 Of these PTS
scoring systems, the Villalta score (Table VII) has the high-
est degree of validation and has been shown to have excel-
lent interobserver reliability, association with ambulatory
venous pressures, correlation with severity of PTS, and abil-
ity to assess change in condition over time.199-205 Evidence
supports use of Villalta scoring in all patients with VLU and
prior documented DVT to determine diagnosis, severity,and treatment outcomes of PTS, with consensus recom-
mendation to combine Villalta with CEAP for more accu-
rate diagnosis of PTS.206
Additional venous disease evaluation should include
patient-oriented quality of life (QOL) assessment. Both
generic (36-Item Short Form Health Survey [SF-36])
and venous diseaseespeciﬁc (Venous Insufﬁciency Epide-
miologic and Economic Study of Quality of Life/Symp-
toms (VEINES-QOL/Sym) questionnaires, the Chronic
Venous Insufﬁciency Questionnaire (CIVIQ), the Aber-
deen Varicose Vein Questionnaire (AVVQ), and the Char-
ing Cross Venous Ulceration Questionnaire (CXVUQ))
have been used and validated for patients with venous
Table VII. Villalta scoring for post-thrombotic
syndrome
Symptoms and clinical signs None Mild Moderate Severe
Symptoms
Pain 0 1 2 3
Cramps 0 1 2 3
Heaviness 0 1 2 3
Paresthesia 0 1 2 3
Pruritus 0 1 2 3
Clinical signs
Pretibial edema 0 1 2 3
Skin induration 0 1 2 3
Hyperpigmentation 0 1 2 3
Redness 0 1 2 3
Venous ectasia 0 1 2 3
Pain on calf compression 0 1 2 3
Venous ulcer Absent Present
Villalta score $5 or if venous ulcer present: Villalta score of 5-9 mild, 10-14
moderate, and $15 severe.
Modiﬁed from Villalta S, Bagatella P, Piccioli A, Lensing AW, Prins MH,
Prandoni P. Assessment of validity and reproducibility of a clinical scale for
the postthrombotic syndrome [abstract]. Haemostasis 1994;24:158a.
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diseaseespeciﬁc QOL more than generic QOL assessment
to be complementary to the more objective provider-based
venous assessment tools. For all patients with VLU, QOL
assessment should be performed with a venous diseasee
speciﬁc instrument to evaluate patient-reported outcome
and severity of CVD.Guideline 3.13: Venous Procedural Outcome
Assessment
We recommend venous procedural outcome assess-
ment including reporting of anatomic success, venous
hemodynamic success, procedure-related minor and
major complications, and impact on venous leg ulcer
healing. [BEST PRACTICE]
Guideline 4.1: Wound Cleansers
We suggest that venous leg ulcers be cleansed
initially and at each dressing change with a neutral,
nonirritating, nontoxic solution, performed with a
minimum of chemical or mechanical trauma. [GRADE -
2; LEVEL OF EVIDENCE - C]For all patients with VLUs who require venous endo-
vascular or operative intervention, outcome assessment
should be performed to determine success of the procedure
over time. Several surrogate outcome markers have been
described for venous procedures, including anatomic
parameters, venous hemodynamic success, procedure-
related complications, and impact on VLU healing.215
Use of recommended reporting standards and participation
in a venous-based registry can facilitate tracking of venous
procedure outcomes.216 Clinical outcome assessment asso-
ciated with wound and procedural treatments allows
further determination of comparative effectiveness for
improved VLU healing as mandated by the Institute of
Medicine of the National Academies (http://www.iom.
edu/) and the U.S. Food and Drug Administration
(FDA).217 In addition, standardized venous outcome
assessment will translate to improved quality care measures
as regulated by quality care organizations, such as theNational Quality Forum (http://www.qualityforum.
org/), the Surgical Care Improvement Project (http://
qualitynet.org/), the Joint Commission (http://www.
jointcommission.org/), and the Agency for Healthcare
Research and Quality (http://www.ahrq.gov), and
increased potential opportunities for National Institutes
of Health funding for research on venous ulcer prevention
and treatment.3
WOUND CARE
A broad array of products and treatment strategies are
currently marketed for the purpose of managing chronic
wounds related to venous hypertension. It is challenging
to determine which of these therapies have meaningful ev-
idence that shows improvement in patient-centered out-
comes, such as pain reduction and wound healing. This
section is organized into general categories related to
wound healing as noted in Table VIII. All of these thera-
pies must be used concurrently with compression therapy
or venous intervention to control the underlying venous
hypertension resulting in ulceration.
Wound Bed Preparation. Wound bed preparation is
deﬁned as the management of the wound to accelerate
endogenous healing and to facilitate the effectiveness of
other therapeutic measures. The aim of wound bed prepa-
ration is to convert the molecular and cellular environment
of a chronic wound to that of an acute healing wound.
Included within this framework are (1) débridement, (2)
wound exudate control, and (3) management of surface
bacteria. Once control of the underlying venous hyperten-
sion is achieved, a key barrier that inhibits wound healing is
eliminated. Other barriers to healing include bacterial over-
growth or infection, chronic inﬂammation, and necrotic or
nonviable tissue on the wound surface. Control of these
factors must also be achieved to stimulate optimal wound
healing. Management of wound exudate is covered in the
wound dressings section, and bacterial management is
considered in the section on infection control.Although there is little evidence that the routine use of
a wound cleanser results in improvement of VLU out-
comes measures, most patients with VLUs present with sig-
niﬁcant wound exudate and other debris in and around the
wound area that must be cleansed routinely before dressing
application. Numerous cleansing solutions have been
described in this role with reasonable success.218,219 It ap-
pears that the main selection factor is to avoid routine use
of a cleanser that would result in toxicity to the viable tissue
in the wound bed.220
Table VIII. General categories of wound therapy for
venous leg ulcers
Wound bed preparation
Wound cleansers
Débridement
Surgical débridement
Anesthesia for débridement
Hydrosurgical débridement
Ultrasonic débridement
Enzymatic débridement
Biologic débridement
Nutritional assessment and management
Measurement of wound progress
Wound infection and bacterial control
Wound culture
Indications for culture
Method of wound culture
Management of limb cellulitis
Wound colonization and bacterial bioﬁlms
Treatment of wound infection
Topical antibiotics
Systemic antibiotics
Primary wound dressings
Topical dressing selection
Antimicrobials in topical dressings
Periulcer skin management
Anti-inﬂammatory dressings
Adjunctive wound therapies
Indications for adjunctive therapies
Split-thickness skin grafting
Cellular therapy
Use of cellular therapy
Preparation for cellular therapy
Frequency of cellular therapy application
Negative pressure therapy
Electrical stimulation
Ultrasound therapy
Guideline 4.2: Débridement
We recommend that venous leg ulcers receive thor-
ough débridement at their initial evaluation to remove
obvious necrotic tissue, excessive bacterial burden, and
cellular burden of dead and senescent cells. [GRADE -
1; LEVEL OF EVIDENCE - B] We suggest that addi-
tional maintenance débridement be performed to
maintain the appearance and readiness of the wound
bed for healing. [GRADE - 2; LEVEL OF EVIDENCE -
B] We suggest that the health care provider choose
from a number of débridement methods, including
sharp, enzymatic, mechanical, biologic, and autolytic.
More than one débridement method may be appro-
priate. [GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 4.3: Anesthesia for Surgical Débridement
We recommend that local anesthesia (topical or local
injection) be administered to minimize discomfort asso-
ciated with surgical venous leg ulcer débridement. In
selected cases, regional block or general anesthesia may
be required. [GRADE - 1; LEVELOF EVIDENCE - B]
Guideline 4.4: Surgical Débridement
We recommend that surgical débridement be per-
formed for venous leg ulcers with slough, nonviable tis-
sue, or eschar. Serial wound assessment is important in
determining the need for repeated débridement.
[GRADE - 1; LEVEL OF EVIDENCE - B]
Guideline 4.5 Hydrosurgical Débridement
We suggest hydrosurgical débridement as an alter-
native to standard surgical débridement of venous leg
ulcers. [GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 4.6: Ultrasonic Débridement
We suggest against ultrasonic débridement over
surgical débridement in the treatment of venous leg ul-
cers. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 4.7: Enzymatic Débridement
We suggest enzymatic débridement of venous leg
ulcers when no clinician trained in surgical débride-
ment is available to débride the wound. [GRADE - 2;
LEVEL OF EVIDENCE - C] We do not suggest enzy-
matic débridement over surgical débridement.
[GRADE - 2; LEVEL OF EVIDENCE - C]
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recommend wound débridement to remove nonviable tissue
and to reduce bacterial burden, there is a lack of robust evi-
dence that routine wound débridement accelerates wound
healing. Williams et al prospectively studied 28 patients
who underwent débridement for the presence of slough
and nonviable tissue in the VLU bed compared with 27
patients who also had little granulation tissue but no slough
and did not receive débridement.221 Patients treated with
débridement had a signiﬁcantly higher wound size reduction4 weeks after débridement than those who did not. This dif-
ference was maintained 20 weeks after débridement. Cardinal
et al reviewed the relationship of débridement to ulcer heal-
ing in two prospective RCTs of topical wound treatments on
366 VLUs and 310 diabetic foot ulcers.222 VLUs treated at a
clinic visit with débridement had a signiﬁcantly higher me-
dian wound surface area reduction in the week after débride-
ment than did those for which débridement was not
performed. However, débridement frequency per patient
did not statistically correlate to rates of wound closure.
Recommendations to débride nonviable or necrotic tis-
sue from the wound bed are supported by established prin-
ciples of management of all wounds.223,224 However, the
frequency and method of débridement are not well studied
and have not been well established as related to the inci-
dence of wound closure.225The efﬁcacy of topical anesthesia for débridement of
venous leg ulcers was recently reviewed by the Cochrane
Database.226 They identiﬁed six trials evaluating eutectic
mixture of local anesthetics (EMLA) lidocaine-prilocaine
cream compared with control.227,228 Patients treated with
EMLA had signiﬁcantly lower pain scores than those
treated without topical anesthetic, leading to their conclu-
sion that EMLA is an effective option for this purpose. For
more extensive débridement, local inﬁltrative anesthetic,
regional block, or general anesthesia may be required for
adequate periprocedural pain control.
Guideline 4.8: Biologic Débridement
We suggest that larval therapy for venous leg ulcers
can be used as an alternative to surgical débridement.
[GRADE - 2; LEVEL OF EVIDENCE - B]
Guideline 4.9: Management of Limb Cellulitis
We recommend that cellulitis (inﬂammation and
infection of the skin and subcutaneous tissue) sur-
rounding the venous leg ulcer be treated with systemic
gram-positive antibiotics. [GRADE - 1; LEVEL OF
EVIDENCE - B]
Guideline 4.10: Wound Colonization and Bacterial
Bioﬁlms
We suggest against systemic antimicrobial treat-
ment of venous leg ulcer colonization or bioﬁlm
without clinical evidence of infection. [GRADE - 2;
LEVEL OF EVIDENCE - C]
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perior to surgical methods. However, in some cases, pa-
tients may not have ready access to a clinician trained to
perform surgical débridement, or this method may be
less desirable because of comorbid patient conditions or
pain considerations. Hydrosurgical débridement was
found in some studies to shorten the procedural time of
débridement but may be associated with signiﬁcant addi-
tional cost.229,230 Hydrosurgical débridement also re-
quires a trained clinician and may be associated with
signiﬁcant periprocedural pain. No measurable beneﬁt of
the use of ultrasound methods to débride wounds has
been reliably demonstrated. Enzymatic débridement,
which does not require a trained clinician for application,
has been found in several studies to remove nonviable tis-
sue from VLU wound beds, but there is no evidence that
this method provides a beneﬁt over surgical débride-
ment.231-233 In clinical trials, larval therapy along with
compression has been shown to be an effective method
of débridement. However, the use of larval therapy did
not increase the rate of healing for necrotic tissue or
slough in leg ulcers compared with ulcers treated with
hydrogel and compression.234,235 Barriers to the use of
larval therapy also include personal hygiene concerns
and personal bias. Recent adaptations have included con-
taining the larvae in a bio-bag, which makes adoption
more feasible to those with these concerns.
Wound Infection and Bacterial Control. The man-
agement of bacterial involvement of chronic VLUs is
controversial, with limited high-quality research and con-
tradictory results in the studies available for review. More
robust information is available for the treatment of other
infected chronic wounds, in particular diabetic foot ulcers.
This information may not translate to the treatment of
infected VLUs.
For indications and methods of wound culture, refer to
Guideline 3.4. Although there is general agreement
among experts that wounds with obvious signs of clinical
infection should be treated with systemic antibiotics, there
is no consensus on the management of wounds colonized
with bacteria or bacterial bioﬁlms without signs of systemic
infection. The deﬁnition of a critically colonized wound is
not universally standardized and may vary by the virulence
of the colonizing bacteria. The more recent description of
bacterial bioﬁlms and the multiple species that are typically
cultured from these wounds add another layer of
complexity. Finally, the changing nature of bacterial
behavior over time may render studies performed as
recently as 5 to 10 years ago irrelevant.
Developing technology, which has allowed more
detailed descriptions of the bacteria found existing in thewound bed, employs methodology such as polymerase
chain reaction analysis. These techniques may allow more
speciﬁc tailored therapy for individual wounds. These
methods, however, have not yet been established to
improve outcomes in the care of VLUs. In this setting,
deﬁnitive guidelines are difﬁcult to establish, and treatment
must be individualized on the basis of local bacterial epide-
miology and patient conditions.Limb cellulitis is characterized by inﬂammation and
infection of the skin, subcutaneous tissue, and lymphatic
ﬂuid and is most commonly due to streptococci or
staphylococci, but it will occasionally include other spe-
cies. There are numerous studies in the medical litera-
ture evaluating various systemic antibiotic regimens for
the treatment of lower extremity cellulitis,236-238 also
supported by a Cochrane review,239 with recommenda-
tion for initial treatment with antibiotics directed at
gram-positive bacteria, reserving broader coverage for
unresponsiveness.The data available concerning the treatment of bacte-
rial colonization of VLUs are insufﬁcient and contradic-
tory. Sibbald et al found that high bacterial counts in
VLUs were associated with delayed healing.240 Improved
healing was associated with reduction in bacterial counts.
Davies et al suggested that bacterial density was predictive
of nonhealing of VLUs.122 However, Lantis and Gendics
found that when they treated VLUs with high bacterial
counts with topical antibiotics, bacterial counts decreased
but there was no correlation with improvement in wound
size.241 Finally, Moore et al reported that the speciﬁc bac-
terial species present or the number of species of bacteria
present did not relate to healing outcomes.118 They
concluded that their data supported no speciﬁc treatment
of wound bacteria regardless of the type or quantity. On
the basis of these contradictory ﬁndings, we are unable to
generate useful supporting clinical guidelines for treatment
of wound colonization or bioﬁlm without clinical evidence
of infection.
Guideline 4.11: Treatment of Wound Infection:
We suggest that venous leg ulcers with >1 3 106
CFU/g of tissue and clinical evidence of infection be
treated with antimicrobial therapy. [GRADE - 2;
LEVEL OF EVIDENCE - C] We suggest antimicrobial
therapy for virulent or difﬁcult to eradicate bacteria
(such as beta-hemolytic streptococci, pseudomonas,
and resistant staphylococcal species) at lower levels
of colony-forming units per gram of tissue. [GRADE -
2; LEVEL OF EVIDENCE - C] We suggest a com-
bination of mechanical disruption and antibiotic ther-
apy as most likely to be successful in eradicating
venous leg ulcer infection. [GRADE - 2; LEVEL OF
EVIDENCE - C]
Guideline 4.12: Systemic Antibiotics
We recommend that venous leg ulcers with clinical
evidence of infection be treated with systemic antibi-
otics guided by sensitivities performed on wound cul-
ture. [GRADE - 1; LEVEL OF EVIDENCE - C]
Oral antibiotics are preferred initially, and the duration
of antibiotic therapy should be limited to 2 weeks un-
less persistent evidence of wound infection is present.
[GRADE - 1; LEVEL OF EVIDENCE - C]
Guideline 4.14: Topical Dressing Selection
We suggest applying a topical dressing that will
manage venous leg ulcer exudate and maintain a moist,
warm wound bed. [GRADE - 2; LEVEL OF EVI-
DENCE - C] We suggest selection of a primary wound
dressing that will absorb wound exudate produced by
the ulcer (alginates, foams) and protect the periulcer
Guideline 4.15: Topical Dressings Containing
Antimicrobials
We recommend against the routine use of topical
antimicrobial-containing dressings in the treatment of
noninfected venous leg ulcers. [GRADE - 2; LEVEL
OF EVIDENCE - A]
JOURNAL OF VASCULAR SURGERY
28S O’Donnell et al August Supplement 2014Although there is a lack of clinical studies evaluating
the speciﬁc treatment of infected VLUs, available evi-
dence supports systemic antibiotic treatment of patients
with clinical evidence of infection and ulcers containing
> 1  106 CFU/g of bacteria on quantitative culture.242
Aggressive mechanical débridement of infected VLUs
whenever possible is also suggested, although there is a
lack of high-quality evidence indicating that débride-
ment improves results in the treatment of infected
ulcers.Guideline 4.13: Topical Antibiotics for Infected
Wounds
We suggest against use of topical antimicrobial
agents for the treatment of infected venous leg ulcers.
[GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 4.16: Periulcer Skin Management
We suggest application of skin lubricants under-
neath compression to reduce dermatitis that commonly
affects periulcer skin. [GRADE - 2; LEVEL OF EVI-
DENCE - C] In severe cases of dermatitis associated
with venous leg ulcers, we suggest topical steroids to
reduce the development of secondary ulcerations and
to reduce the symptoms of dermatitis. [GRADE - 2;
LEVEL OF EVIDENCE - C]There is a lack of evidence suggesting that topical anti-
biotics have a positive effect on the treatment of infected
VLUs or on the healing of noninfected VLUs. Manizgate
et al reported that in a prospective study of two silver-
releasing dressings, neither dressing had an impact on the
level of bioburden identiﬁed in treated VLUs.243
Conversely, in another study, Lantis and Gendics found
that a sustained-release silver sulfadiazine foam reduced
the level of bacteria cultured from infected VLUs, but there
was no correlation with an improvement in wound size.241
A Cochrane review on the use of topical silver for infected
VLUs concluded that there is insufﬁcient evidence to
recommend the use of silver-containing dressings or topical
agents for treatment of infected or contaminated chronic
wounds.244Primary Wound DressingsThere is insufﬁcient evidence suggesting that a speciﬁc
primary dressing that contacts the wound can result in a
higher rate of wound closure. Most VLUs produce large
amounts of exudate. This ﬂuid contains high concentra-
tions of proteases and inﬂammatory cytokines that may
damage surrounding healthy skin.245 Removal of wound
drainage from the wound bed will reduce the inﬂammatory
environment that prohibits wound healing. We recom-
mend use of dressings that will manage wound exudate
and maintain a moist wound bed. Primary dressings with
high absorptive capabilities, including foams, alginates,
and other specialty dressings, are often selected for the pri-
mary coverage layer for heavily exudative VLUs.246
skin. [GRADE - 2; LEVEL OF EVIDENCE - B]In the only prospective RCT of topical antibiotics, which
examined the treatment of noninfected VLUs, Michaels et al
randomized 213 patients with VLUs to silver-releasing dress-
ings compared with non-silver-releasing dressings.247 No sig-
niﬁcant difference in ulcer healing or other quality of life
measures was identiﬁed in the silver dressing group. Given
the increased cost of silver-containing dressings, routine use
of topical antimicrobial dressings for the treatment of VLUs
is not supported.248,249Management of dermatitis and other abnormalities of
the periulcer skin is an important adjunct to other therapies
in the treatment of VLUs.250 Venous hypertension may
cause signiﬁcant dermatitis in the calf and ankle that may
be ameliorated with a variety of skin lubricants and other
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other products used to treat VLUs is also frequent. Recog-
nizing this problem and treating it expeditiously will pre-
vent secondary skin ulceration complicating the primary
leg ulcer.251,252 Consultation from dermatology may be
useful in long-standing or recurrent cases experiencing
sensitivity to wound treatment products.Guideline 4.17: Anti-inﬂammatory Therapies
We suggest against use of anti-inﬂammatory thera-
pies for the treatment of venous leg ulcers. [GRADE -
2; LEVEL OF EVIDENCE - C]Although a signiﬁcant body of research has identiﬁed
that VLUs are associated with signiﬁcant upregulation of
inﬂammatory cytokines and proteases,71,83,253 there is a
lack of data identifying that any anti-inﬂammatory dressing
other than compression is associated with accelerated heal-
ing of VLUs.254
Adjunctive Wound TherapiesGuideline 4.18: Indications for Adjuvant Therapies
We recommend adjuvant wound therapy options for
venous leg ulcers that fail to demonstrate improvement
after a minimum of 4 to 6 weeks of standard wound Guideline 4.20: Cellular Therapy
We suggest the use of cultured allogeneic bilayer
skin replacements (with both epidermal and dermal
layers) to increase the chances for healing in patients
with difﬁcult to heal venous leg ulcers in addition to
compression therapy in patients who have failed to
show signs of healing after standard therapy for 4 to
6 weeks. [GRADE - 2; LEVEL OF EVIDENCE - A]
Guideline 4.21: Preparation for Cellular Therapy
We suggest a therapeutic trial of appropriate
compression and wound bed moisture control beforeAdjunctive therapies for the healing of VLUs should be
considered after all standard of care measures have been
implemented. Comprehensive care should include compres-
sion therapy, local wound débridement, control of bio-
burden, wound moisture balance with appropriate
dressings, and consideration of the use of pentoxifylline. Af-
ter a minimum of 4 to 6 weeks of appropriate care, a
decrease in wound dimensions should be noted. Standard
of care for VLUs will lead to improvement in the majority
of cases, and only in those cases without improvement
should adjunctive modalities be used. The cost of these ther-
apies can be high, and the evidence supporting their use is
not sufﬁciently strong to justify their use as primary therapy
without an attempt at lower cost, evidence-based methods.
However, failure to demonstrate improvement after 4 weeks
of treatment with a decrease in wound size of at least 30% to
40% should lead the clinician to consider adjunctive treat-
ment options.109 Re-evaluation of the patient and wound
should be performed before the use of adjuvant therapies
to ensure that compression has achieved edema control, bio-
burden is well controlled, and exudate is not excessive.
therapy. [GRADE - 1; LEVEL OF EVIDENCE - B]Guideline 4.19: Split-thickness Skin Grafting
We suggest against split-thickness skin grafting as
primary therapy in treatment of venous leg ulcers.
[GRADE - 2; LEVEL OF EVIDENCE - B] We suggest
split-thickness skin grafting with continued compres-
sion for selected large venous leg ulcers that have failed
to show signs of healing with standard care for 4 to 6
weeks. [GRADE - 2; LEVEL OF EVIDENCE - B]There is currently insufﬁcient information to recom-
mend use of autologous skin grafting as a primary therapy
for VLUs. Studies have bias, small sample size, and indirect
comparators. A Cochrane review on skin grafting for VLUs
also failed to reach a deﬁnitive recommendation.255 A
recent RCT found that use of low-molecular-weight hepa-
rin resulted in decreased recurrence compared with skin
grafting without anticoagulation.256,257 After skin grafting,
patients should continue to use therapeutic compression.
Individual situations and patient preferences might
result in the use of skin grafting for VLUs. Some clinicians
consider skin grafting after standard of care has failed, for
large soft tissue defects, by the patient’s or clinician’s pref-
erence, and when there are speciﬁc reasons that require
more expeditious closure. In a nonrandomized study of
111 patients, Jankunas demonstrated improved healing
and durability with skin grafting compared with conserva-
tive therapy for large venous wounds that were present
longer than 6 months,, but only 65% of cases were judged
to have good take of the split-thickness skin graft.258 Skin
grafting should be considered as primary therapy only for
large wounds (ie, >25 cm2) in which healing is unlikely
without grafting or as secondary therapy after there is a fail-
ure to achieve healing with standard of care.Apligraf, an allogeneic bilayer cellular therapy, has been
approved by the FDA for treatment of VLUs. The efﬁcacy
of Apligraf was studied in an RCT of 245 patients with
VLUs treated with standard of care compared with standard
of care plus the application of Apligraf.259,260 VLUs had been
present for at least 6 weeks and had not responded well to the
initial use of compression and the other aspects of standard
care. Subsequent research has identiﬁed improved outcomes
for recalcitrant VLUs (>1 year duration or large surface
area).262 No other living cellular therapies have demonstrated
beneﬁt for the treatment of VLUs in prospective RCTs.application of cellular therapy. [GRADE - 2; LEVEL
OF EVIDENCE - C] We recommend that adequate
wound bed preparation, including complete removal of
slough, debris, and any necrotic tissue, be completed
before the application of a bilayered cellular graft.
[GRADE - 1; LEVEL OF EVIDENCE - C] We recom-
mend additional evaluation and management of increased
bioburden levels before the application of cellular ther-
apy. [GRADE - 1; LEVEL OF EVIDENCE - C]
Guideline 4.22: Frequency of Cellular Therapy
Application
We suggest reapplication of cellular therapy as long
as the venous leg ulcer continues to respond on the ba-
sis of wound documentation. [GRADE - 2; LEVEL OF
EVIDENCE - C]
Guideline 4.25: Electrical Stimulation
We suggest against electrical stimulation therapy
for venous leg ulcers. [GRADE - 2; LEVEL OF EVI-
DENCE - C]
Guideline 4.26: Ultrasound Therapy
We suggest against routine ultrasound therapy for
venous leg ulceration. [GRADE -2; LEVEL OF EVI-
DENCE - B]
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biologic skin substitutes to VLUs remain controversial
with little consensus in published studies. The initial pivotal
trial for Apligraf allowed up to ﬁve applications of the prod-
uct during the ﬁrst 3 weeks of the study.259 Reapplication
was performed if the investigator thought that there was
less than 50% “take” of the skin equivalent on inspection
of the wound. Subsequent to this clinical trial, it has
been determined that living skin equivalents do not persist
in the wound for more than a few weeks, so “no take” oc-
curs as is seen with autologous grafts. Other studies have
reported application at variable times, including weekly,
every few weeks, or once only.261 With no comparative
dosing studies published to determine clinical or economic
outcomes, the frequency of application remains at the
discretion of the clinician. Current clinical practice has
included application of grafts followed by a period of 1
to 3 weeks of observation to determine effectiveness before
reapplication is considered.Guideline 4.23: Tissue Matrices, Human Tissues,
or Other Skin Substitutes
We suggest the use of a porcine small intestinal sub-
mucosa tissue construct in addition to compression
therapy for the treatment of venous leg ulcers that
have failed to show signs of healing after standard ther-
apy for 4 to 6 weeks. [GRADE - 2; LEVEL OF EVI-
DENCE - B]Numerous tissue constructs are available for use in
chronic wounds that employ either human tissue (amniotic
membrane, cryopreserved skin) or animal tissue (bladder,
fetal bovine skin, others). Some are reported to contain
active growth factors or other attributes that might be
beneﬁcial to healing of VLUs.262 Of the multitude of
such products currently marketed, only porcine small intes-
tinal submucosa has prospective RCT data supporting its
use to accelerate VLU closure.263Guideline 4.24: Negative Pressure Therapy
We suggest against routine primary use of negative
pressure wound therapy for venous leg ulcers.
[GRADE - 2; LEVEL OF EVIDENCE - C]There is currently not enough information to support
the primary use of negative pressure wound therapy for
VLUs. Evidence supports positive effects with the use of
negative pressure therapy for wound healing in general.
Tissue granulation, area and volume reduction, and reduc-
tions in bioburden have all been reported. There have beenfew studies speciﬁcally studying negative pressure therapy
for VLUs, with most studies reporting on mixed wound
causes.264 There has been an increase in the use of negative
pressure wound therapy for wound bed preparation to
augment skin graft healing.265There is theoretical, preclinical, and limited clinical ev-
idence to support the use of electrical stimulation for the
treatment of VLUs.266 However, few studies of electrical
stimulation focus solely on VLUs. Also, there is little con-
sistency in the parameters of treatment, including vari-
ability in type of electrical current, settings, treatment
times, and preferred waveforms, making comparisons
impossible.267,268 For these reasons, electrical stimulation
is not recommended for the treatment of VLUs until
further evidence supports its use.Therapeutic ultrasound has been found to stimulate a
number of cellular effects associated with the acceleration
of wound healing. These cellular effects have been well
studied in vitro and include improvement of microcircula-
tion, reduction of edema, and increases in cytokine and
other protein levels that are active in the healing
cascade.269 Clinical trials studying the effects of ultrasound
have reported positive results in the healing of a variety of
chronic nonhealing wounds.270 Clinical trials of therapeu-
tic ultrasound for the healing of VLUs lack standardized
protocols, and relatively few studies focus on VLUs alone.
In a pilot study of VLUs refractory to compression therapy,
ultrasound treatment was associated with a decrease in
wound size, inﬂammatory cytokines, bacterial counts, and
pain.271 In an RCT of 337 VLU patients, weekly treatment
with high-frequency ultrasound did not result in an in-
crease in healing rates or improved quality of life compared
with standard VLU care.272 Unfortunately, most therapeu-
tic ultrasound protocols have recommended treatment ses-
sions at higher frequency, such is three times weekly or
once daily. This has led to criticism of this trial as suffering
from inadequate ultrasound dosing to determine whether
it provides any beneﬁt to patients with VLUs. Additional
studies employing a standardized protocol of therapeutic
ultrasound in patients with VLUs are required for further
recommendations on the use of this modality to be
made.273 On the basis of current literature, there is insufﬁ-
cient evidence to recommend the routine use of therapeu-
tic ultrasound for the treatment of VLUs as a primary
therapy.
Guideline 5.1: CompressiondUlcer Healing
In a patient with a venous leg ulcer, we recommend
compression therapy over no compression therapy to
increase venous leg ulcer healing rate. [GRADE - 1;
LEVEL OF EVIDENCE - A]
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adjuvant treatments with evidence suggestive of beneﬁt
for patients with VLUs that do not respond to an initial
treatment course of standard therapy. Split-thickness skin
grafting may provide beneﬁt, particularly for large, recalci-
trant VLUs. Cellular therapy with Apligraf was found to be
beneﬁcial in a multicenter randomized clinical trial, as was
porcine small intestinal submucosa. There have been no
comparative trials of these therapies published with sufﬁ-
cient evidence to recommend one therapy over the others
for the treatment of recalcitrant VLUs.
COMPRESSION
Compression therapy is based on a mechanical concept
of applying pressure to the limb. This simple action causes
multiple biologic processes proved to be beneﬁcial for man-
agement of conditions ranging from occupational swelling
to venous ulcers. A variety of devices have been used for
compression therapy. Different types of bandages, bandage
systems, and ready-to-use garments can provide sustained
compression, whereas several pneumatic devices apply
intermittent compression.
For the treatment of VLU, compression systems, which
exert hemodynamic improvement on the dysfunctional
venous pumping function, are preferred. Such systems
that do not give way to the expanding muscle during
walking are either short-stretch textiles or multicomponent
bandages containing elastic material in combination with
an adhesive or cohesive covering layer. Such bandages
need to be applied by trained staff. Self-applicable and
adjustable short-stretch Velcro band devices may be an
alternative. Elastic bandages or compression stockings are
effective concerning edema reduction but are hemodynam-
ically less effective in improving the venous pumping
function.274
Bandage layers should be differentiated from compo-
nents. The term multilayer describes one bandage that al-
ways covers the leg with more than one layer because of
overlapping during application. Every multicomponent
bandage is a multilayer bandage, whereas graduated
compression stockings have a single compression layer.
The four-layer bandage (4LB) is a multicomponent
bandage consisting of four components: orthopedic wool,
crepe bandage, elastic bandage, and elastic cohesive (outer)
bandage. Applying several components and layers over
each other not only increases the pressure but also changes
the elastic property of the ﬁnal bandage because of the fric-
tion between the surfaces of each bandage and a cohesive
outer layer, producing a ﬁnal multilayer bandage that is
less elastic and more stiff. Short-stretch bandages (SSB)
are also often used as multicomponent bandages in combi-
nation with different materials. Unfortunately, the different
combinations of materials are often poorly described in
trials.
Coexistence of multiple devices that are designed to
perform essentially the same function demonstrates that
although compression therapy is generally effective, the
optimization of compression has been a challenging taskbecause of limitations in current evidence. Use of confusing
terminology and not reporting the dose (pressure) of a
compression device and physical properties of the compres-
sion product are just a few of many deﬁciencies in available
evidence related to compression therapy.275 The use of
pressure-measuring devices at the skin-bandage interface
to ensure adequate pressure applied during the bandaging
is not routine; however, in speciﬁc circumstances (such as
study protocol and quality assurance), such instruments
can be applied.276,277A total of nine RCTs compare compression therapy to
no compression therapy, and these trials provide objective
information on initial ulcer size as well as the outcomes
of time to complete healing or proportion of ulcers healed
(FDA-recommended end points of wound therapy trials).
The preponderance of evidence suggests that VLUs heal
more quickly with compression therapy vs no compression
as conﬁrmed by our commissioned comparative systematic
review and meta-analysis of compression modalities and
venous ulcer healing.30
One RCT of 36 patients directly compared compres-
sive (Unna boot) with noncompressive bandages (polyure-
thane foam dressing). Wound healing rates were
signiﬁcantly improved by 0.07 cm2/day (P ¼ .004), and
more patients completely healed in the compression group
(RR, 2.30; 95% CI, 1.29-4.10).278,279
A recent Cochrane review identiﬁed three RCTs
encompassing a total of 177 patients comparing compres-
sion dressings with primary dressing alone (never with
compression).279 One study (44 patients) showed a differ-
ence with improved ulcer area and volume at 8 weeks.280
Two of the studies (49 and 84 patients) failed to show a
difference in healing rates between treatments at 7 weeks
and 6 months of follow-up, respectively.281,282
Another RCT of 321 patients compared SSB or 4LB
with moist wound dressings without compression. The
healing rate at 24 weeks was superior in both compression
groups (72% SSB and 67% 4LB) compared with the non-
compression group (29%; P < .0001).283
Three of four additional RCTs that compared
compression dressings with standard wound care found
improvement in ulcer healing with compression therapy.
One study (53 patients) compared SSB with usual care
and found complete ulcer healing at 3 months to be 71%
in the SSB group compared with 25% in the usual care
group (P value not reported).284 The remaining studies
compared 4LB dressing with primary care management.
A trial of 36 patients found more complete healing at 3
months in the compression group compared with the usual
care group (RR, 4.0; 95% CI, 1.35-11.82).285 Similar
Guideline 5.3: Multicomponent Compression
Bandage
We suggest the use of multicomponent compres-
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ticipants, with 54% of patients healed in the 4LB group
compared with 34% in the control group (P < .001).286
Another RCT of 233 patients failed to ﬁnd a difference be-
tween two groups with regard to complete healing at 1
year but did ﬁnd improved rate of healing (median time
of 20 vs 43 weeks; P ¼ .03) favoring the compression
group.287Guideline 5.2: CompressiondUlcer Recurrence
In a patient with a healed venous leg ulcer, we sug-
gest compression therapy to decrease the risk of ulcer
recurrence. [GRADE - 2; LEVEL OF EVIDENCE - B]
sion bandage over single-component bandages for the
treatment of venous leg ulcers. [GRADE - 2; LEVEL
OF EVIDENCE - B]
Guideline 5.4: CompressiondArterial Insufﬁciency
In a patient with a venous leg ulcer and underlying
arterial disease, we do not suggest compression ban-
dages or stockings if the ankle-brachial index is 0.5 or
less or if absolute ankle pressure is less than 60 mm
Hg. [GRADE - 2; LEVEL OF EVIDENCE - C]The potential for recurrence of VLUs is high as
demonstrated by a 67% recurrence rate in one study, in
which 35% of patients exhibited a remarkable four or
more episodes of ulceration.140 The reported recurrence
rate for ulcers in one study in the setting of compression
therapy alone is 28% and in combination with superﬁcial
venous surgery is 12%, highlighting the recent improve-
ments in clinical practice.288
As more success is achieved with healing of primary
VLUs, the number of patients at risk for recurrence
rises.289 However, few RCTs have speciﬁcally evaluated
the impact of compression therapy on the risk of ulcer
recurrence. One trial randomized 153 patients with
recently healed (2 weeks) VLU to compression or no
compression therapy. Compression hosiery with a high
pressure (34-46 mm Hg) was associated with signiﬁcant
reduction in ulcer recurrence at 6 months compared with
no compression (21% vs 46%; RR, 0.46; 95% CI, 0.27-
0.76; P ¼ .003).289,290 A second RCT of 188 patients ran-
domized 166 into two treatment groups, each receiving
therapy with 23 mm Hg compression at the ankle with
two brands of stockings. Compliance data reported from
this trial as summarized in Nelson and Bell-Syer demon-
strated that inability to tolerate compression therapy was
signiﬁcantly associated with recurrent ulceration (RR,
2.58; 95% CI, 1.33-5.01; P ¼ .010), although these pa-
tients were not included in randomization.289,291
These RCT data are congruent with 15 years of obser-
vational data demonstrating that lack of compliance with
compression therapy was signiﬁcantly associated with ulcer
recurrence (16% recurrence with compliance, 100%
without; P < .0001).292 Two studies to date have evalu-
ated the use of moderate (UK class II, 18-24 mm Hg at
the ankle) to high (UK class III, 25-35 mm Hg) compres-
sion and compliance with these stockings on prevention of
ulcer recurrence, with differing results. One study found no
difference in recurrence between the two groups but signif-
icantly lower compliance in the high-compression
group.293 Because time to recurrence was not reported,
the effect of compression pressures on delay of recurrence
remains unknown.On the basis of our commissioned comparative system-
atic review and meta-analysis of compression modalities
and venous ulcer healing, low-quality evidence supports
the effect of compression on ulcer recurrence.30The possible difference in healing outcomes between
single-layer and multilayer compression bandages has
been evaluated in four trials, three of which have been pub-
lished. In two trials, the number of participants was small
(n ¼ 27 and 34) and showed no difference between treat-
ment groups.279,294,295 However, a large RCT with 245
patients demonstrated improved healing at 24 weeks
(67% vs 49%; P ¼ .009) in the multilayer (4LB) bandage
group compared with the single-layer group.296 In addi-
tion, 4LB were associated with faster wound closure (78
vs 168 days; P ¼ .001) compared with the single-layer
group.
A recent meta-analysis identiﬁed six trials directly
comparing multicomponent bandages containing elastic
with those not containing elastic. Data from 797 patients
(ﬁve trials with independent patient data available) demon-
strated 30% improved healing with 4LB compared with
those with SSB (odds ratio, 1.31; 95% CI, 1.09-1.58;
P ¼ .0005).297 These data might in part be explained by
the skill of the health care professional in achieving optimal
sub-bandage pressures and graduated compression. In
comparing 4LB with SSB in countries where the medical
staff is familiar with applying SSB (eg, Netherlands and
Austria), there was no signiﬁcant difference between the ul-
cer healing rates after 3 months (33 of 53 ¼ 62% healed
with 4LB vs 43 of 59 ¼ 73% with SSB).297-299 Studies
comparing different versions of the 4LB (proprietary and
nonproprietary) were similar in outcomes, and thus a spe-
ciﬁc 4LB is not endorsed.300-302
On the basis of our commissioned comparative system-
atic review and meta-analysis of compression modalities
and venous ulcer healing, moderate-quality evidence sup-
ports multicomponent compression over single component
compression.30An ABI of less than 0.5 is considered to be indicative
of severe arterial disease.303 Compression of a limb with
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perfusion and potentially result in adverse ischemic
sequelae. In a survey study, nearly one third of general
surgery consultants surveyed reported that they had
encountered ulcers or necrosis as the direct result of
compression treatment.304 Supporting evidence is limited
to a small number of case reports and a dated physiology
study that examined the effects of compression on the up-
per extremity in healthy subjects.305-307 However, one
study using magnetic resonance ﬂowmetry showed that
sustained compression with a pressure around 40 mm
Hg increases the arterial ﬂow under the bandage in
normal volunteers.308 Similarly, a recent study performed
in patients with VLUs and concomitant arterial occlusive
disease (ABI of 0.5 to 0.85) demonstrated by multiple
metrics that arterial blood ﬂow is even augmented by in-
elastic bandages.309
For patients with VLU and concomitant PAD, use of
standard compression has been shown to be safe if ABI
$0.80.303,310,311 Modiﬁed compression bandages or
compression stockings with lower pressure ratings can be
used for ankle systolic pressure $60 mm Hg, digital pres-
sure $30 mm Hg or ABI $0.50 with close monitoring,
but only after consultation with a vascular specialist.309,312
Use of ankle perfusion pressure of 60 mm Hg or greater
rather than ABI #0.5 as a cutoff for compression is
preferred because this correlates better with tissue perfu-
sion pressure, and any sustained external compression pres-
sure should never exceed this cutoff perfusion pressure.
One study showed that modiﬁed compression multilayered
bandages with reduced compression pressure can be bene-
ﬁcial for healing of mixed ulcers.311Guideline 5.5: Intermittent Pneumatic Compression
We suggest use of intermittent pneumatic compres-
sion when other compression options are not available,
cannot be used, or have failed to aid in venous leg
ulcer healing after prolonged compression therapy.
[GRADE - 2; LEVEL OF EVIDENCE - C]Intermittent pneumatic compression (IPC) was
initially proposed as a method to promote VLU healing
by activation of the ﬁbrinolytic system and showed prom-
ise in decreasing VLU healing time in patients who had
previously failed to respond to conservative treat-
ment.313,314 However, this theory remains to be rigor-
ously tested. To date, only 387 patients have been
enrolled in RCTs comparing IPC with other treatment
modalities.36 Whereas it is advantageous to use IPC
compared with no compression therapy, currently there
is limited evidence to suggest that the addition of IPC
to compression therapy offers beneﬁt.315 Thus, the pa-
tients likely to beneﬁt most from IPC are those who
cannot tolerate or do not have access to compressiontherapy or who have failed to respond to prolonged
compression therapy alone. Further studies need to be un-
dertaken to evaluate the beneﬁt of IPC in this particular
cohort. In circumstances in which IPC is used, there is
some evidence to suggest that proportion of ulcers healed
(86% vs 61% at 6 months; P ¼ .003) is improved with
rapid compared with slow cycling.316OPERATIVE/ENDOVASCULAR MANAGEMENT
Guidelines for operative and endovascular manage-
ment are categorized anatomically as superﬁcial venous dis-
ease, perforator venous disease, deep infrainguinal venous
disease, and iliocaval disease. Each category can be
managed with open surgical or endovascular techniques.
The rare occurrence of congenital venous disease leading
to VLU and its treatment lacks deﬁnitive reporting.
These guidelines for operative and endovascular man-
agement also address the twofold goal of VLU treatment,
which includes ulcer healing and prevention of ulcer recur-
rence. The separate pathologic processes of primary degen-
erative reﬂux disease and inﬂammatory thrombotic disease
provide different challenges for the treating physician
because the surgeon or interventionalist must provide a
speciﬁc procedure to correct the pathologic state.
In general, quality of the evidence available to support
recommendations for operative and endovascular manage-
ment is mostly limited to level C evidence because of an
absence of comparative prospective RCTs of treatment
techniques, with the exception of superﬁcial venous treat-
ments. The strength of the clinical recommendations for
operative and endovascular management can be increased
by concurrence of results from individual case series
and expert opinion of the Venous Ulcer Guidelines
Committee.
This section is predicated on the principle that deep
vein reconstruction is reserved for cases in which there
has been failure to control the ulcer diathesis by dedi-
cated nonsurgical measures and by simpler conventional
interventions in the superﬁcial and perforator veins of
the extremity. In general, less invasive procedures are
preferred when they are available and equally effective.
Concurrence has been negatively affected because of
the evolving developmental status of open surgery for
complicated pathologic states in the deep veins of the
leg, pelvis, and abdomen and the ongoing search for
minimally invasive procedures. Within these limitations,
there is growing consensus that the endovascular stent-
ing techniques are the most appropriate surgical treat-
ment for iliac occlusive disease, whereas open
autogenous repair is best therapy for deep vein reﬂux in
the infrainguinal lower extremity or from failed endove-
nous stent procedures of the iliocaval and iliofemoral
venous system. A practical algorithm for operative and
endovascular management of patients with VLUs is pro-
posed in the Fig.
Fig. Proposed algorithm for operative and endovascular treatment of patients with venous leg ulcer (VLU) based on
involved anatomic venous system and presence of venous reﬂux or obstruction. The risk-to-beneﬁt ratio is weighed for
those procedures with more risk (lower, moderate, higher) considered later in the treatment when the beneﬁt is similar.
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Venous Leg UlcerdUlcer Healing
In a patient with a venous leg ulcer (C6) and
incompetent superﬁcial veins that have axial reﬂux
directed to the bed of the ulcer, we suggest ablation
of the incompetent veins in addition to standard
compressive therapy to improve ulcer healing.
[GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.2 Superﬁcial Venous Reﬂux and Active
Venous Leg UlcerdPrevent Recurrence
In a patient with a venous leg ulcer (C6) and
incompetent superﬁcial veins that have axial reﬂux
directed to the bed of the ulcer, we recommend abla-
tion of the incompetent veins in addition to standard
compressive therapy to prevent recurrence. [GRADE -Our commissioned comparative systematic review and
meta-analysis of surgical interventions vs conservative
therapy including 11 studies (seven RCTs and four obser-
vational studies) favored open surgery vs compression for
ulcer healing, although the quality of the evidence was
low.31 In addition, other individual RCTs have shown a
1; LEVEL OF EVIDENCE - B]difference that was not statistically signiﬁcant favoring sur-
gical treatment of the superﬁcial venous system and
compression over compression alone.31,288,317 On the ba-
sis of these observations, the strength and grade of evi-
dence favoring surgery for ulcer healing are limited to a
Grade 2C classiﬁcation. Regarding recurrence, our
commissioned comparative systematic review and meta-
analysis included two RCTs, and each study favored
surgery plus compression over compression alone to a
statistically signiﬁcant degree for prevention of ulcer
recurrence.288,317,318 Because each study had some chal-
lenges in design and baseline imbalance, the strength
and grade of evidence is 1B.
Regarding the choice of method of saphenous abla-
tion, there are multiple RCTs showing strong and consis-
tent evidence that modern open surgery, radiofrequency,
and laser ablation are equivalent in effect and safety
(Table IX).319-330 Endovenous ablation can be extrapo-
lated to be as effective as open ligation and stripping
used in these earlier trials. Moreover, endovenous ablation
can be carried out under local/tumescent anesthesia as an
ofﬁce-based procedure, which shifts the risk/beneﬁt ratio
signiﬁcantly. Foam sclerotherapy has been demonstrated
to rival these modalities and has signiﬁcantly more recan-
alizations and reﬂuxing treated segments on follow-up
Table IX. Randomized controlled trials of endovenous laser or radiofrequency ablation vs open surgery for the treatment
of great saphenous vein incompetence (at least 1 year of follow-up) comparing recurrence of varicose veins and
neovascularization
Year No. of patients Follow-up, years
Results
Recurrence Neovascularization
Endovenous laser ablation vs open surgery
Lin et al319 2007 80 1 No difference No difference
Theivacumar et al320 2009 120 2 No difference þ Laser
Christenson et al321 2010 200 2 No difference No difference
Pronk et al322 2010 130 1 No difference No difference
Carradice et al323 2011 280 1 þ Laser No difference
Rass et al324 2012 346 2 No difference No difference
Rasmussen et al325 2013 137 5 No difference No difference
Endovenous radiofrequency ablation vs open surgery
Lurie et al326 2005 65 2 No difference No difference
Perala et al327 2005 28 3 No difference No difference
Kianifard et al328 2006 55 1 No difference þ Radiofrequency
Stötter et al329 2006 60 1 No difference No difference
Helmy ElKaffas et al330 2010 180 2 No difference No difference
þ Laser, Favored in comparison of laser vs open surgery; þ Radiofrequency, favored in comparison of radiofrequency vs open surgery.
Guideline 6.5: Combined Superﬁcial and Perfo-
rator Venous Reﬂux With or Without Deep Venous
Reﬂux and Active Venous Leg Ulcer
In a patient with a venous leg ulcer (C6) and
incompetent superﬁcial veins that have reﬂux to the ul-
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der investigation, including steam ablation and pharmaco-
mechanical and cyanoacrylate ablation as well as CHIVA
(ambulatory conservative hemodynamic management of
varicose veins; one small RCT showed that CHIVA had
a higher proportion of ulcers heal than with compression
alone) and ASVAL (ambulatory selective varicose vein
ablation under local anesthesia).20,257,333-338Guideline 6.3: Superﬁcial Venous Reﬂux and
Healed Venous Leg Ulcer
In a patient with a healed venous leg ulcer (C5) and
incompetent superﬁcial veins that have axial reﬂux
directed to the bed of the ulcer, we recommend abla-
tion of the incompetent veins in addition to standard
compressive therapy to prevent recurrence. [GRADE -
1; LEVEL OF EVIDENCE - C]
Guideline 6.4: Superﬁcial Venous Reﬂux With Skin
Changes at Risk for Venous Leg Ulcer (C4b)
In a patient with skin changes at risk for venous leg
ulcer (C4b) and incompetent superﬁcial veins that have
axial reﬂux directed to the bed of the affected skin, we
suggest ablation of the incompetent superﬁcial veins in
addition to standard compressive therapy to prevent ul-
ceration. [GRADE - 2; LEVEL OF EVIDENCE - C]
cer bed in addition to pathologic perforating veins
(outward ﬂow of >500 ms duration, with a diameter
of >3.5 mm) located beneath or associated with the ul-
cer bed, we suggest ablation of both the incompetent
superﬁcial veins and perforator veins in addition to
standard compressive therapy to aid in ulcer healing
and to prevent recurrence. [GRADE - 2; LEVEL OF
EVIDENCE - C]The evidence supporting this guideline is an extrapola-
tion of the data on ulcer healing and prevention of ulcer
recurrence stated under Guidelines 6.1 and 6.2. In this
group of patients, VLUs had healed, and so intervention
is expected to provide protection from recurrence as noted
in our commissioned comparative systematic review and
meta-analysis and the two RCTs.31,288,317,318Perforator Venous Reﬂux and Venous Leg UlcerThe evidence regarding treatment of perforator venous
reﬂux associated with a VLU is complicated by several fac-
tors but most notably by combining its treatment with that
of superﬁcial venous reﬂux.339-352 The Dutch RCT
comparing subfascial endoscopic perforator vein surgery
(SEPS) with or without superﬁcial reﬂux ablation to med-
ical treatment in patients with venous ulcers found no dif-
ference in healing rate or recurrence in the two treatment
groups.317 However, patients with recurrent ulceration or
medially located ulcers in the surgical group had a longer
ulcer-free period than did those treated in the conservative
group (P ¼ .02). A secondary analysis of the Dutch SEPS
trial on 94 ulcerated legs was reported with a mean follow-
up of 29 months.353 Ulcer recurrence was signiﬁcantly
higher in patients who had an incomplete SEPS procedure
(P ¼ .007), indicating the clinical signiﬁcance of incompe-
tent perforating veins in patients with venous ulcers.
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involving 1140 treated limbs found that surgical treatment
by SEPS, with or without superﬁcial venous ablation, resulted
in ulcer healing in 88% and a low ulcer recurrence of 13% at
21 months.340 Another meta-analysis concluded that perfo-
rator interruption used as a part of a treatment regimen for
severe CVI beneﬁts most patients in the short term regarding
ulcer healing and the prevention of ulcer.345Guideline 6.6: Combined Superﬁcial and Perfo-
rator Venous Reﬂux With or Without Deep Venous
Disease and Skin Changes at Risk for Venous Leg Ulcer
(C4b) or Healed Venous Ulcer (C5)
In a patient with skin changes at risk for venous leg
ulcer (C4b) or healed venous ulcer (C5) and incompe-
tent superﬁcial veins that have reﬂux to the ulcer bed in
addition to pathologic perforating veins (outward ﬂow
of >500 ms duration, with a diameter of >3.5 mm)
located beneath or associated with the healed ulcer
bed, we suggest ablation of the incompetent superﬁcial
veins to prevent the development or recurrence of a
venous leg ulcer. [GRADE - 2; LEVEL OF EVI-
DENCE - C] Treatment of the incompetent perfo-
rating veins can be performed simultaneously with
correction of axial reﬂux or can be staged with re-
evaluation of perforator veins for persistent incompe-
tence after correction of axial reﬂux. [GRADE - 2;
LEVEL OF EVIDENCE - C]
Guideline 6.8: Treatment Alternatives for Patho-
logic Perforator Veins
For those patients who would beneﬁt from patho-
logic perforator vein ablation, we recommend treat-
ment by percutaneous techniques that include
ultrasound-guided sclerotherapy or endovenous ther-
mal ablation (radiofrequency or laser) over open
venous perforator surgery to eliminate the need for in-
cisions in areas of compromised skin. [GRADE - 1;
LEVEL OF EVIDENCE - C]A recent systematic review that included analysis of 12
practice guidelines and four RCTs concluded that perforating
vein interruption should be reserved for patients with large
pathologic perforators with advanced CVI, and evidence sug-
gests no added beneﬁt in patients with less severe disease (C2,
C3).340 The procedure can be performed either combined
with or staged to follow superﬁcial vein ablations, and those
with long-standing and large medial ulcers or recurrent ulcer-
ations have the chance to beneﬁt most. In the North Amer-
ican SEPS registry, factors associated with ulcer healing
included SEPS with concomitant ablation of superﬁcial reﬂux
and lack of deep venous obstruction (P < .05).354,355Guideline 6.7: Pathologic Perforator Venous
Reﬂux in the Absence of Superﬁcial Venous Disease,
With or Without Deep Venous Reﬂux, and a Healed
or Active Venous Ulcer
In a patient with isolated pathologic perforator veins
(outward ﬂow of >500 ms duration, with a diameter of
>3.5 mm) located beneath or associated with the healed
(C5) or active ulcer (C6) bed regardless of the status of
the deep veins, we suggest ablation of the “pathologic”
perforating veins in addition to standard compression
therapy to aid in venous ulcer healing and to prevent
recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]There is no RCT that evaluated the effect of isolated
perforator interruption on ulcer healing or recurrence.Results of the SEPS registry, however, found that ulcer
recurrence in 57 patients who underwent SEPS without
saphenous ablation was not signiﬁcantly higher than recur-
rence after combined venous surgery.354 Endovenous inter-
ventions, as discussed in Guideline 6.8, will undoubtedly
bring new evidence to corroborate the efﬁcacy of perforator
ablations in the treatment of venous ulcers.Endovenous techniques, including radiofrequency
and laser ablations as well as foam sclerotherapy of perfo-
rating veins, have gained increasing acceptance because
of the minimally invasive nature of these interven-
tions.23,342-344,346-348,350 Therapy can be repeated with
ease, risk of complications is minimal, and early to
midterm results in case series are equivalent to or better
than those reported after conventional perforating vein
interruptions.356-358 The risks of open procedures, which
speciﬁcally include infection, difﬁculty in healing of inci-
sions required for treatment, increased local trauma, and
need for general anesthesia, set open operations apart
from these less invasive percutaneous methods. In one
of the larger series of 140 consecutive endovenous abla-
tion procedures (74 superﬁcial and 66 perforator) on
110 venous ulcers in 88 limbs, there was measurable
and signiﬁcant reduction in ulcer size and ultimate heal-
ing after ablation of incompetent superﬁcial and perfo-
rator veins in patients for whom conventional
compression therapy had failed.337,348
Deep Venous Obstruction/Reﬂux and Venous Leg
Ulcer. For the following recommendations involving deep
venous obstruction or reﬂux, patients with VLUs being
evaluated for deep venous intervention should have already
been evaluated and treated for any superﬁcial or perforator
reﬂux per Guidelines 6.1 to 6.8. For the remaining
Guidelines 6.9 to 6.17, the status of the deep venous sys-
tem is the only pathologic process requiring treatment. The
risks of open procedures, which speciﬁcally include infection,
difﬁculty in healing of incisions required for treatment,
increased local trauma, hematoma formation, and need for
general anesthesia, set open operations apart from the less
invasive percutaneous methods. As a result, in patients
with clinically signiﬁcant iliac and caval obstruction com-
bined with infrainguinal reﬂux or obstruction, percutaneous
balloon angioplasty with stenting is suggested as the initial
procedure over deep venous valvular reconstructions or
open operative bypass procedures because it is much less
invasive and presents less risk to the patient.
Guideline 6.9: Infrainguinal Deep Venous
Obstruction and Skin Changes at Risk for Venous
Leg Ulcer (C4b), Healed (C5) or Active (C6) Venous
Leg Ulcer
In a patient with infrainguinal deep venous obstruc-
tion and skin changes at risk for venous leg ulcer (C4b),
healed venous leg ulcer (C5), or active venous leg ulcer
(C6), we suggest autogenous venous bypass or endo-
phlebectomy in addition to standard compression ther-
apy to aid in venous ulcer healing and to prevent
recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]
Guideline 6.11: Deep Venous Reﬂux With Skin
Changes at Risk for Venous Leg Ulcer (C4b), Healed
(C5) or Active (C6) Venous Leg UlcerdPrimary Valve
Repair
In a patient with infrainguinal deep venous reﬂux
and skin changes at risk for venous leg ulcer (C4b),
healed venous leg ulcer (C5), or active venous leg ulcer
(C6), we suggest individual valve repair for those who
have axial reﬂux with structurally preserved deep
venous valves in addition to standard compression
therapy to aid in venous ulcer healing and to prevent
recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]
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cated by the variable combinations of reﬂux and obstruction
that may be encountered from the calf to the inferior vena
cava. There will frequently be a mixture of primary valve
reﬂux and post-thrombotic secondary venous occlusion at
different levels of the venous tree, and decisions as to the
most critical site of disease have to be made from detailed
preoperative anatomic analysis of the extremity veins. The
principles that guide the choice of an individual procedure
include the need for adequate inﬂow pressure and volume
into and out of the repaired segments and preferential use
of autogenous tissue for each element of the repair. Often,
there is need to combine various techniques, such as endo-
phlebectomy with bypass or with valve repair or venous
transplantation. All of the techniques described in this and
the following Guideline sections are potential choices that
might be used in combination with endophlebectomy to
provide the inﬂow and outﬂow needed for success. Evidence
shows a preponderance of successful results for all tech-
niques in 40% to 60% of cases with follow-up of 2 to 4
years.359-371 Variations occur according to the status of
the inﬂow vessels in the extremity and the outﬂow vessels
from the common femoral vein.
On the basis of evidence for patients with lower ex-
tremity infrainguinal deep venous obstruction, autogenous
venous bypass or endophlebectomy is suggested, depend-
ing on the status of inﬂow and outﬂow vessels.367-371 Chal-
lenges exist with identiﬁcation of physiologic degrees of
obstruction and the quality of the obstructed vein that
will determine the need for autogenous vein bypass
conduit. Future expansion of endovascular techniques in
combination with endophlebectomy can be predicted in
this area.372,373Guideline 6.10: Deep Venous Reﬂux With Skin
Changes at Risk for Venous Leg Ulcer (C4b), Healed
(C5) or Active (C6) Venous Leg UlcerdLigation
In a patient with infrainguinal deep venous reﬂux
and skin changes at risk for venous leg ulcer (C4b),
healed venous leg ulcer (C5), or active venous leg ulcer
(C6), we suggest against deep vein ligation of the
femoral or popliteal veins as a routine treatment.
[GRADE - 2; LEVEL OF EVIDENCE - C]Ligation of the femoral and popliteal veins without well-
demonstrated collateral pathways risks an increase of outﬂowobstruction and is not recommended unless effective collat-
erals can be identiﬁed. Several case reports support ligation
of the femoral vein as a method of eliminating physiologi-
cally signiﬁcant reﬂux of the femoral vein when the collateral
pathways of both great saphenous and deep femoral veins
are patent and competent.374-377Several techniques are used to fashion an incompetent
valve into a competent valve. External banding refers to a
synthetic sleeve placed around the circumference of a valve
to reduce the vein circumference and to produce a compe-
tent valve. External valvuloplasty is the technique of placing
sutures along the valve attachment line of the intact vein to
decrease the vein diameter with or without actually engaging
the valve leaﬂets. The commissural angle is decreased with or
without actual leaﬂet tightening to allow the valve cusps to
properly appose and to prevent valve prolapse. Internal val-
vuloplasty requires open venotomy to allow direct visualiza-
tion of the valve leaﬂets so that sutures can be accurately
placed to reef or pull the cusps into alignment and to reduce
redundancy until a competent valve has been restored.
External banding can achieve acceptable results in well-
selected patients with early vein dilation. Long-term ulcer
healing has been reported in about 50% of patients with
one valve repair, and improved long-term results have
been reported with multiple reconstructions.378-381
External valvuloplasty results vary by technique, with
the advocates of the “commissural repair” reporting a com-
petency rate of w60% and freedom from ulcer recurrence
rate of w70% at 3 years.382 Others have reported lower
competency (down to 32%) and ulcer-free rates (down to
50%) at 2 years. Proper patient selection is a critical variable
in the results obtained. Overall, this technique appears
applicable and effective in select patients, with expectations
of a 50% ulcer-free rate at 2 years.377-380,383-390
Internal valvuloplasty is an anatomically precise tech-
nique that has been modiﬁed over time. Although internal
valvuloplasty provides the longest durability, it is technically
more demanding and highly operator dependent. This tech-
nique is subject to higher complication rates than external re-
pairs. Serial case series have demonstrated valve competency
rates of 60% to 70% at 5 to 8 years and similar ulcer-free rates
(Table X).368,377,391-396 Representative series of internal val-
vuloplasty interventions in patients with advanced disease
show that most patients included in these studies had healed
Table X. Evidence summary for internal valvuloplasty
Year No. of limbs Follow up, range (average), months Valve Competent Symptom resolved/healed
Ferris and Kistner391 1982 32 12-156 (72) 72.7% 81.2%
Ericksson392 1990 19 44 68.4% 73.7%
Cheatle and Perrin393 1994 52 3-54 85.2% 86.3%
Masuda et al376 1994 32 48-252 (127) 77.5% 71.9%
Raju et al378 1996 81 12-144 42.3% 76.5%
Sottiurai368 1997 143 9-168 75% 75%
Perrin395 2000 85 12-96 (58) 61.5% 71.4%
Tripathi and Ktenidis396 2001 25 1-12 (6) 85.4% 84.0%
Tripathi et al377 2004 90 (24) 79.9% 67.7%
Table XI. Evidence summary for venous valve
transposition
Year
No.
of limbs
Follow-up,
months
Valve
competence
Ulcer
recurrence
Johnson et al400 1981 12 18 d 33%
Masuda et al376 1992 14 120 40% d
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results in patient with VLUs that have proved recalcitrant
to healing with other forms of treatment.363,391-393,397-399
Among these are comparable studies performed indepen-
dently by experienced venous reconstructive surgeons who
report a consistent range of successful results with long-
term follow-up at 1, 5, and 7 years.363,376,378Guideline 6.12: Deep Venous Reﬂux With Skin
Changes at Risk for Venous Leg Ulcer (C4b), Healed
(C5) or Active (C6) Venous Leg UlcerdValve Trans-
position or Transplantation
In a patient with infrainguinal deep venous reﬂux
and skin changes at risk for venous leg ulcer (C4b),
healed venous leg ulcer (C5), or active venous leg ulcer
(C6), we suggest valve transposition or transplantation
for those with absence of structurally preserved axial
deep venous valves when competent outﬂow venous
pathways are anatomically appropriate for surgical
anastomosis in addition to standard compression ther-
apy to aid in venous leg ulcer healing and to prevent
recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]
Sottiurai401 1996 20 9-149 40% 56%
Cardon et al402 1999 16 24-120 75% 44%
Perrin395 2000 17 12-168 53% 25%
Lehtola et al403 2008 14 24-78 43% d
Guideline 6.13: Deep Venous Reﬂux With Skin
Changes at Risk for Venous Leg Ulcer (C4b), Healed
(C5) or Active (C6) Venous Leg UlcerdAutogenous
Valve Substitute
In a patient with infrainguinal deep venous reﬂux
and skin changes at risk for venous leg ulcer (C4b),
healed venous leg ulcer (C5), or active venous leg ulcer
(C6), we suggest consideration of autogenous valve
substitutes by surgeons experienced in these techniques
to facilitate ulcer healing and to prevent recurrence in
those with no other option available in addition to
standard compression therapy to aid in venous ulcer
healing and to prevent recurrence. [GRADE - 2;
LEVEL OF EVIDENCE - C]Venous valve transposition requires that a competent
valve, or one that can be made competent, be placed above
the site where the incompetent venous systems are
implanted into the axial vein. One example would be the
presence of a competent valve in the proximal deep femoral
vein, below which the incompetent femoral vein can be
implanted to result in a then competent femoral venous
system. In the select cohort of patients who are amenable
to this intervention, a 40% to 50% competency rate with
similar freedom from ulcer recurrence has been reported
in a number of case series reports at 5 years of follow-up
(Table XI).376,391,395,399-405
Venous valve transplantation involves harvesting of a
competent segment of vein that contains a competent valve
from another extremity and implanting it into the femoral or
popliteal position to provide a functioning valve in the
affected extremity. Adjunctive use of endophlebectomy
and the need for an arteriovenous ﬁstula to increase ﬂow
through the reconstruction sites are additional consider-
ations. The long-term competency rate at 2 to 5 years is
w50%, with a slightly higher freedom from ulcer recurrence
rate.359-368,377,405,406 Table XII includes representativeseries of venous valve transplantation conducted in patients
with C3-6 disease, with most conducted in patients with
C5,6 disease. Multiple small case series are reported with
similar results for both techniques, with restored compe-
tence in the range of 40% to 60% for more than 2 years.
Anatomic variations determine which procedure can be
used in a given case. Both procedures can be effective for
short-term ulcer healing, but both are subject to late failure
of valve competence. A late failure of competence does not
necessarily result in recurrence of ulceration.Autogenous venous valve substitutes use venous tissue to
make a functioning venous valve with pieces of vein tissue or
endoluminal scar to fashion competent valves by various tech-
niques. These include suturing of tissue in place within the
opened vein; invagination of the stump of the great saphenous
vein into the femoral vein with appropriate sutures placed to
act as a valve; use of tacking sutures to secure the anterior
Table XII. Evidence summary for venous valve transplantation
Year No. of limbs Follow-up, range (average), months Valve competent Symptom resolved/healed
Taheri et al365 1986 46 8-36 91.7% 89.1%
Nash366 1988 25 12-18 80% 92.0%
Iafrati and O’Donnell405 1997 15 (64) 92% 82%
Perrin363 1997 30 12-120 (58) 30% 60%
Sottiurai368 1997 33 8-169 (89) 38.7% 45.1%
Raju et al406 1999 83 12-180 83% 60%
Tripathi et al377 2004a 38 (24) 47.5% 55.3%
aImproved results with multiple valves repaired.
Guideline 6.15: Proximal Chronic Venous Occlu-
sion/Severe Stenosis (Bilateral) With Recalcitrant
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patch used to replace the anterior wall; and dissection of the
intimal-medial wall of the often postphlebitic vein to form a
monocuspid or bicuspid valve, with proper sutures placed to
form a functioning valve. Regarding the ﬁrst three techniques,
small case series have been reported, but they lack corrobora-
tive series from other surgeons. Raju and Hardy reported ﬁve
of seven patients to have healed recalcitrant VLUs within 4
months without recurrence during a 15- to 24-month obser-
vation period by use of the ﬁrst technique.383 Great saphenous
vein invagination has been reported in a single series, with 19
of 20 repairs remaining patent and competent at 10 months of
follow-up, with all VLUs healing within 6 months and no re-
currences observed.407,408 The valve made of the anterior vein
wall with synthetic patch repair has reported excellent clinical
results (80% or better) for the ﬁrst year, but the number of
cases reported is small.
Creation of monocuspid or bicuspid valves from the
endoluminal lining of the post-thrombotic or even the pri-
mary diseased vein wall (neovalve) has been reported from
a single site. It has undergone modiﬁcations over the years,
and recent reports show 85% patency/competency rate
with about 85% healed and ulcer-free recurrence rate at a
mean of 28 months. All valves were patent. There was a
95% ulcer healing rate and two recurrent ulcers.409,410
These techniques are performed in cases that are highly
selected and have no other known valvular restorative po-
tential. The procedures must be considered technically
challenging and still in need of corroborative data before
wider dissemination. Their use should be limited to experi-
enced venous reconstructive surgeons in patients without
other viable options.Guideline 6.14: Proximal Chronic Total Venous
Occlusion/Severe Stenosis With Skin Changes at Risk
for Venous Leg Ulcer (C4b), Healed (C5) or Active
(C6) Venous Leg UlcerdEndovascular Repair
In a patient with inferior vena cava or iliac vein
chronic total occlusion or severe stenosis, with or
without lower extremity deep venous reﬂux disease,
that is associated with skin changes at risk for venous
leg ulcer (C4b), healed venous leg ulcer (C5), or active
venous leg ulcer (C6), we recommend venous angioplasty
and stent recanalization in addition to standard compres-
sion therapy to aid in venous ulcer healing and to prevent
recurrence. [GRADE - 1; LEVEL OF EVIDENCE - C]There is recognition of the importance of iliac vein
obstruction in both primary and post-thrombotic
CVD.175,411,412 Profound proximal obstruction in the ilio-
caval veins appears to be the predominant hemodynamic
pathophysiologic process compared with peripheral reﬂux
when both exist, although deﬁnitive proof of this has not
been tested. As a result, treatment priority is generally
accorded to the proximal occlusive disease when one is
faced with combined proximal obstruction and distal
valvular reﬂux. Percutaneous iliac and caval vein stenting
has been proved safe, with low morbidity, high patency,
and satisfactory efﬁcacy. Current results demonstrate a cu-
mulative patency rate of 90% with ulcer healing rates of
60% to 80%, depending on the cohort being treated
(Table XIII).173,413-418 Percutaneous iliac and caval vein
stenting has become the preferred technique of many cen-
ters for iliocaval and some common femoral vein occlusive/
stenotic conditions, such as the post-thrombotic condition
or that of the May-Thurner primary disorder when it is
technically achievable.419-427 Extension of the iliac vein
stent below the inguinal ligament did not result in stent
fracture, erosion, arteriovenous ﬁstula, or higher incidence
of stent thrombosis than is inherent to post-thrombotic
disease.428 In the presence of combined iliac obstruction
and infrainguinal reﬂux, treatment of the iliac obstruction
is recommended as the ﬁrst procedure, with repair of reﬂux
below the iliac level reserved for persistently symptomatic
cases.Venous UlcerdOpen Repair
In a patient with inferior vena cava or iliac vein
chronic occlusion or severe stenosis, with or without
lower extremity deep venous reﬂux disease, that is asso-
ciated with a recalcitrant venous leg ulcer and failed
endovascular treatment, we suggest open surgical bypass
with use of an externally supported expanded polytetra-
ﬂuoroethylene graft in addition to standard compression
therapy to aid in venous leg ulcer healing and to prevent
recurrence. [GRADE - 2; LEVEL OF EVIDENCE - C]Most series suggest the need for large conduits from
normal distal to normal proximal vein with supportive arte-
riovenous ﬁstula to increase ﬂow during early healing. No
Table XIII. Evidence summary for endovascular iliocaval stents placed for total venous occlusive disease
Year No. of limbs/limbs with ulcers Follow-up, years Cumulative patency % Ulcers healed
Venous stenosis
Hartung et al413 2009 89/6 7 93% 83%
Meng et al414 2011 272/78 5 94% 85%
Raju and Neglen173 2006 99/19 (inferior vena cava only) 4 82% 62%
Neglen et al415 2007 982/167 6 Nonthrombotic: 100%
Thrombotic: 86%
58%
Ye et al416 2012 224/63 4 99% 82%
Chronic total occlusions
Raju and Neglen417 2009 139/32 4 66% 58%
Rosales et al418 2010 34/7 7 90% 57%
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centers report a beneﬁt and have been summarized in
recent reviews.371,373,429-433Guideline 6.16: Unilateral Iliofemoral Venous
Occlusion/Severe Stenosis With Recalcitrant Venous
UlcerdOpen Repair
In a patient with unilateral iliofemoral venous oc-
clusion/severe stenosis with recalcitrant venous leg ul-
cer for whom attempts at endovascular reconstruction
have failed, we suggest open surgical bypass with use
of saphenous vein as a cross-pubic bypass (Palma pro-
cedure) to aid in venous ulcer healing and to prevent
recurrence. A synthetic graft is an alternative in the
absence of autogenous tissue. [GRADE - 2; LEVEL
OF EVIDENCE - C]
Guideline 7.1: Nutrition Assessment and
Management
We recommend that nutrition assessment be per-
formed in any patient with a venous leg ulcer who
has evidence of malnutrition and that nutritional sup-
plementation be provided if malnutrition is identiﬁed.
[BEST PRACTICE]Anumber of case series report experiences with the cross-
pubic bypass, a femoral vein to femoral vein bypass with use of
autogenous vein. Patency has been based on clinical outcome
and not objective assessment in earlier series, whereas more
recent case series using venography or duplex ultrasonogra-
phy to assess patency report 5-year secondary patency rates
ofw75%. Risk factors for suboptimal outcomes include the
low pressure in the venous system, a small saphenous vein
(<5 mm), and technical imperfections such as kinking of
the graft. A prosthetic bypass for venous obstruction is a
salvage procedure when endovenous stenting or venous
bypass is not feasible. Lower overall patency rates than with
a Palma procedure can be expected.371,431,434-436Guideline 6.17: Proximal Chronic Total Venous
Occlusion/Severe Stenosis (Bilateral or Unilateral)
With Recalcitrant Venous UlcerdAdjunctive Arterio-
venous Fistula
For those patients who would beneﬁt from an open
venous bypass, we suggest the addition of an adjunctive
arteriovenous ﬁstula (4-6 mm in size) as an adjunct to
improve inﬂow into autologous or prosthetic crossover
bypasses when the inﬂow is judged to be poor to aid in
venous leg ulcer healing and to prevent recurrence.
[GRADE - 2; LEVEL OF EVIDENCE - C]An adjunctive arteriovenous ﬁstula has been used to
enhance patency after venous procedures. An arteriove-
nous ﬁstula can produce distal venous hypertension if
the ﬁstulas are too large. Because this pressure difference
will negate the purpose of a venous bypass performed
for relief of venous hypertension, use of an arteriove-
nous ﬁstula should be temporary and its size should
be controlled to avoid excessive ﬂow. A suitably sized
prosthetic sleeve around the ﬁstula is one method to
achieve this effect and allows later percutaneous closure
with coil.437-440
ANCILLARY MEASURES
In addition to speciﬁc treatments for VLU, such as
wound care, compression therapy, and operative/endovas-
cular interventions described in prior guidelines, some
ancillary complementary measures have been used to
improve ulcer healing.441-449 This section reviews nutri-
tion, systemic drug therapy, physiotherapy, lymphatic mas-
sage, and balneotherapy options.Nutrition must be adequate to provide sufﬁcient pro-
tein to support the growth of granulation tissue. Although
most VLU patients are ambulatory and not as nutritionally
depleted as patients who require frequent or chronic hospi-
talization, nutritional support is required if an individual is
undernourished.450,451 Deﬁciency in vitamins A and E,
carotene, proteins, and zinc was found in patients with
VLUs.452 In addition, elderly individuals susceptible to
development of ulcers may have insufﬁcient intake of pro-
teins, vitamins, and minerals.453-455 These patients demon-
strate improved ulcer healing rates when these deﬁciencies
are corrected. However, no beneﬁcial effect was demon-
strated in supplementing patients without deﬁciencies.450
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patients with VLUs refractory to treatment after 4 months
of oral administration of zinc sulfate (220 mg three times
daily), ﬁve other trials failed to conﬁrm these results.457Guideline 7.2: Systemic Drug Therapy
For long-standing or large venous leg ulcer, we
recommend treatment with either pentoxifylline or
micronized puriﬁed ﬂavonoid fraction used in combi-
nation with compression therapy. [GRADE - 1;
LEVEL OF EVIDENCE - B]
Guideline 7.3: Physiotherapy
We suggest supervised active exercise to improve
muscle pump function and to reduce pain and edema
in patients with venous leg ulcers. [GRADE - 2;
LEVEL OF EVIDENCE - B]
Guideline 7.4: Manual Lymphatic Drainage
We suggest against adjunctive lymphatic drainage for
healing of the chronic venous leg ulcers. [GRADE - 2;
LEVEL OF EVIDENCE - C]Several systemic drugs have been evaluated for their
potential role in improving VLU healing. Noting the limita-
tion of oxygen diffusion in ulcerations by a pericapillary
ﬁbrin cuff,458,459 an RCT comparing stanozolol (anabolic
steroid with proﬁbrinolytic effect) with placebo was per-
formed, but despite previously demonstrated activity on lip-
odermatosclerosis in CVD, the drug failed to show
superiority over placebo.460 A randomized multicenter
placebo-controlled trial of another proﬁbrinolytic and
antithrombotic drug, sulodexide (puriﬁed glycosamino-
glycan), was encouraging and showed improved VLU heal-
ing in 235 patients treated for 3 months.461 Platelet
inhibitors have also been studied in RCTs of VLUs, but
aspirin and ifetroban (oral thromboxane A2 receptor antag-
onist) have failed to show beneﬁcial effect on healing.462,463
Prostaglandin E1 is known for properties that reduce white
cell activation and platelet aggregation and increase vasodi-
lation. An intravenous treatment with prostaglandin E1 was
tested in VLUs and demonstrated reduced time to healing,
improved complete healing rate, and improvement in other
outcomes pertinent to chronic venous disorders, such as
edema and venous symptoms.464-466 The constraint of
intravenous infusion (3 hours daily for 6 weeks), however,
makes this therapy difﬁcult to recommend. The discovery
of the involvement of leukocytes in the pathophysiologic
mechanism of VLUs has opened another pathway for suc-
cessful investigations.467
Two systemic drugs interacting with leukocyte activa-
tion have demonstrated an effect on VLU healing, micron-
ized puriﬁed ﬂavonoid fraction (MPFF or Daﬂon)14,468-476
and pentoxifylline.286,474,477-483 MPFF protects the micro-
circulation from the damage induced by venous ambulatory
hypertension. Clinical outcome measures in ﬁve RCTs of
VLUs and a meta-analysis (723 patients involved) showed
that adjunctive to compression therapy and local wound
care, MPFF increased the healing rate (at 6 months, relative
risk reduction was 32%; 95% CI, 3%-70%) and shortened
time to ulcer healing,29-31 with a favorable cost-effective-
ness31,32 and improved venous symptoms.28,29 MPFF is
used worldwide but is not FDA approved in the United
States. Pentoxifylline was initially developed to treat PAD
and has been used off label in VLUs. It has a powerful
inhibitory effect on cytokine-mediated neutrophil activa-
tion, white cell adhesion to endothelium, and oxidative
stress.484 In nine RCTs (eight vs placebo) including a totalof 572 patients, pentoxifylline combined with compression
improved ulcer healing with a relative risk ratio compared
with placebo of 1.4 [95% CI, 1.19-1.66].477The goal of physiotherapy in treating VLUs is to
decrease venous pressure and edema. This can be achieved
through activation of the calf muscle pump by speciﬁc ex-
ercises of the ankle or by biomechanical stimulation of the
calf muscle pump. Lifestyle changes and a medical program
of speciﬁc exercises (individual or in group) can improve
both calf muscle function and ankle mobility. The
improved function of the calf muscle pump results in
both improved ejection fraction and residual volume of
the venous reservoir. VLU patients showed signiﬁcantly
reduced values of ankle range of motion, walking speed
and endurance, self-perceived exertion, mobility, and phys-
ical activity level.485-487 A recent literature review that stud-
ied the importance of lifestyle changes and self-care
activities in preventing recurrence of VLUs identiﬁed 16
studies. This review concluded that there is some evidence
to support a beneﬁcial impact of increased physical activity,
improved mobility, and foot exercises on lowering recur-
rence.488 A Dutch RCT investigated the effectiveness of
the Lively Leg self-management program and showed a
decrease in the duration of VLUs and increased use of
leg exercises in patients who received the additional lifestyle
counseling.461 The time to recurrence and compliance to
compression, however, were not affected. Other online
coaching and home-based exercises programs were success-
fully developed.489-491 Two prospective studies focused on
the impact of supervised exercise. An RCT in patients with
skin changes or ulceration demonstrated a signiﬁcant
improvement of calf pump function after a 6-month pro-
gram of structured exercise.492 Another study concluded
that even a short 7-day period of supervised isotonic calf
muscle exercises in patients with VLUs improves global he-
modynamics in limbs with ulceration.493 A program of
venous rehabilitation that includes four phases of training
(warming, exercises on a speciﬁc bike, walking, and relaxa-
tion) showed some beneﬁt in a recent study.494 Because
mobilization of the foot and ankle joint increases venous
reﬁlling and reduces venous pressure, passive manipulation
of the ankle has been also proposed, but there is no evi-
dence of the beneﬁcial effect for VLUs. Orthopedic treat-
ment might be indicated for foot anomalies, but there is
no evidence supporting improvement of venous plantar
pump function.
Guideline 8.1: Primary PreventiondClinical CEAP
C3-4 Primary Venous Disease
In patients with clinical CEAP C3-4 disease due to
primary valvular reﬂux, we recommend compression,
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well established as an effective therapy in patients with lym-
phedema. Manual lymphatic drainage increases the trans-
port capacity of the lymphatics, stimulates development
of lymphatic collaterals, and softens ﬁbrotic tissue. This is
suggested as a good adjunctive treatment in some resistant
ulcers associated with venolymphatic edema, but there is
no formal supporting evidence.495 One RCT showed that
lymph drainage improved the mobility of the ankle joint
affected bydermatoﬁbrosis in patientswith chronic ulcerated
lesions but did not show beneﬁt in ulcer healing.496Guideline 7.5: Balneotherapy
We suggest balneotherapy to improve skin tro-
phic changes and quality of life in patients with
advanced venous disease. [GRADE - 2; LEVEL
OF EVIDENCE - B]
20 to 30 mm Hg, knee or thigh high. [GRADE - 2;
LEVEL OF EVIDENCE - C]Balneotherapy, spa therapy, or thermalism was studied
in some European centers that specialize in the treatment
of CVD.497 This complex therapy might beneﬁt patients
with VLUs because of mobilization of ﬂuids and decrease
of edema; improvement of venous hemodynamic, microcir-
culation, and skin oxygenation; and increase in circulatory
treatment velocity. The efﬁcacy of hydromassage therapy
with thermal water has been demonstrated in patients
with varicose veins. The beneﬁcial results were attributed
to the favorable action of hydrostatic pressure, which stim-
ulated venous ﬂow, as well as to the characteristics of the
thermal water used in this study.498 Another trial also
concluded that hydrotherapy may help patients suffering
from primary varicose veins.499 An RCT showed that spa
therapy, associated with balneotherapy and patient educa-
tion, signiﬁcantly and durably improved trophic skin
changes, quality of life, and symptoms in patients with
CVD but did not ﬁnd a difference in VLU
recurrences.497Guideline 7.6: Ultraviolet light
We suggest against use of ultraviolet light for the
treatment of venous leg ulcers. [GRADE - 2; LEVEL
OF EVIDENCE - C]Ultraviolet light has been proposed for the treatment
of VLUs to increase skin blood ﬂow and to reduce hypoxia.
However, the results of one clinical prospective study
showed that ultraviolet irradiation improves skin oxygena-
tion for only 48 hours, and therefore it cannot be recom-
mended until there is further supporting evidence.500
PRIMARY PREVENTION
VLUs develop because of ambulatory venous hyper-
tension, which is related primarily to venous valvular reﬂux.
Meaningful ways to prevent VLUs in patients at risk are
effective but limited by lack of provider knowledge of diag-
nosis and treatment and patient compliance with theprimary means of prevention, which is compression.
Equally important for prevention of VLUs in patients
with DVT is adherence to evidence-based guidelines
for prevention of DVT recurrence. In this section, current
evidence for therapies related to primary prevention of
VLUs is reviewed.The concept behind compression is to reduce edema
and inﬂammation related to venous hypertension in the
lower limbs, particularly in the gaiter region, where
VLUs are most likely to develop. Patients may progress
from C2 to C3-C6 at 2% per year.501 Patients with C3-4
disease have a moderate risk of progressing to venous stasis
ulceration, depending on their comorbidities and lifestyle
habits.502 One study has shown that approximately one
third of patients with signiﬁcant reﬂux progress in CEAP
class during 19 months.503 Several risk factors for progres-
sion have been identiﬁed. Obese patients who stand for
prolonged periods may be at higher risk than active nonob-
ese patients, whereas patients with altered iron metabolism
have been shown to have an increased risk for VLU.55
Unfortunately, there are no prospective studies of large
populations that deﬁne the risk of progression to C6
disease.504
Typically, limbs that go on to ulcerate have signiﬁcantly
worse ejection fraction and increased residual volume frac-
tion by air plethysmography.505 Improvement in calf mus-
cle function (ejection fraction) and reduced residual
volume fraction are the primary mechanisms of compres-
sion.506,507 A recent meta-analysis showed that leg symp-
toms, primarily pain and edema, are also signiﬁcantly
improved with use of compression.508 The types of
compression as well as the length and grade of the garment
vary among the different manufacturers. Overall, no evi-
dence exists that one type of compression, duration, or
stocking length is more efﬁcacious than any other. Nega-
tive gradient compression hose with up to 60 mm Hg
calf and 50 mm Hg foot are associated with improvement
in calf muscle pump function compared with graduated
compression.509,510
We recommend 20 to 30 mm Hg compression with
the length (knee high or thigh high) determined by patient
preference. Compliance with compression is important for
its beneﬁcial effect yet may not always be well documented
or emphasized. Difﬁculty in application of compression
garments may play a role in noncompliance, which may in-
crease with higher compression levels.508 Other reasons
exist for noncompliance, including transient conditions
such as pregnancy or recent venous surgery.501,511 Good
compliance produces effective results. For example, in a
large population-based study, most patients with C1-4
Guideline 8.3: Primary PreventiondAcute DVT
Treatment
As post-thrombotic syndrome is a common preced-
ing event for venous leg ulcers, we recommend current
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improved swelling, heaviness, and pain with overall >70%
compliance during 6-year follow-up.501 Unlike treatment
for VLU recurrence prevention, when compression is
used for prophylaxis against VLU in those at risk, there is
no evidence that high levels of compression are more effec-
tive than lesser. A meta-analysis of 11 RCTs of compression
for CVI suggested that the level of compression needed to
be at least 10 to 15 mm Hg, but higher levels were not
necessarily beneﬁcial.508 Thus, as a balance between effec-
tiveness and compliance, the more moderate compression
level is recommended. Last, follow-up after prescription
of compression is important to address the patient’s needs
related to compression ﬁtting and may be a way to enhance
compliance. Although weak evidence exists, compression
may decrease long-term costs associated with CVI. In a
Markov decision analysis, use of compression was associ-
ated with an estimated savings of $17,000 during a pa-
tient’s lifetime.512 However, this study used a
hypothetical patient with C5 disease and did not directly
assess lower clinical classes of venous reﬂux. Regardless,
this study provides support for use of compression in those
at risk for VLU without signiﬁcant downside to use of
compression.Guideline 8.2: Primary PreventiondClinical CEAP
C1-4 Post-thrombotic Venous Disease
In patients with clinical CEAP C1-4 disease related
to prior deep venous thrombosis (DVT), we recom-
mend compression, 30 to 40 mm Hg, knee or thigh
high. [GRADE - 1; LEVEL OF EVIDENCE - B]
evidence-based therapies for acute DVT treatment.
[GRADE - 1; LEVEL OF EVIDENCE - B] We suggest
use of low-molecular-weight heparin over vitamin K
antagonist therapy of 3-month duration to decrease
post-thrombotic syndrome. [GRADE - 2; LEVEL OF
EVIDENCE - B] We suggest catheter-directed throm-
bolysis in patients with low bleeding risk with iliofe-
moral DVT of duration <14 days. [GRADE - 2;
LEVEL OF EVIDENCE - B]Venous reﬂux related to PTS typically is associated with
more severe symptoms than is primary valvular reﬂux, pro-
gresses to a more severe CEAP class, and may confer
increased risk for VLU.513,514 Venous occlusion does in-
crease the risk of severe CVI, as the thrombus becomes a
thick and collagen-dense occlusive lesion.503 Combined
deep and superﬁcial disease is likely after DVT and is asso-
ciated with higher CEAP class.515 The entire vein wall is
often damaged by the thrombotic process, even with recan-
alization, as demonstrated by duplex ultrasound. Whether
a segment of the deep vein system remains occluded or is
recanalized, normal venous function is lost. After recanali-
zation, the valves are incompetent, with signiﬁcant
reﬂux.516
Given the more aggressive long-term course of PTS,
we recommend 30 to 40 mm Hg compression hose, either
knee or thigh high. Two large RCTs support the use of
compression to decrease the occurrence of PTS.197,517,518
Overall, a reduction of w50% was observed. Lesser
compression strength, such as 20 to 30 mm Hg, is not as
effective.519 Multilayer compression is effective only for
symptoms and not for development of PTS.520 The dura-
tion of compression for efﬁcacy has not been rigorously
determined by prospective studies.521 However, per the
current American College of Chest Physicians 2012 guide-
lines, use of compression stockings immediately afterdiagnosis of DVT and continued compression for at least
6 months to 2 years are supported.522 A large recent
RCT calls this into question, but for now, we believe the
harms for this therapy are low.523
Use of IPC may be helpful to relieve PTS symptoms,
but its role in preventing VLU is unknown.524,525 Use of
IPC should be based on individual assessments as little ev-
idence exists. A small randomized crossover trial in patients
with PTS found that compared with placebo-level pressure,
IPC with a level of compression of 50 mm Hg was associ-
ated with a signiﬁcant improvement in symptoms.524 How-
ever, the hard end point of VLU prevention was not
assessed. Two other groups of patients who may beneﬁt
from IPC are those with severe difﬁculty in donning stan-
dard compression stockings and those who are immo-
bile.526,527 Here, studies focusing on the physiology of
decreased venous pressure and reduced interstitial edema
suggest beneﬁt for the latter group.The goal of DVT treatment is twofold: ﬁrst, to pre-
vent venous embolization to the pulmonary circulation
from the thrombus; and second, to prevent propagation
and recurrence of DVT, a direct factor for PTS. Venous
stasis ulceration is the end-stage manifestation of PTS
and is disabling and even limb-threatening.528 PTS treat-
ment is primarily palliative, and thus prevention of DVT
is paramount. There are numerous risk factors for PTS
development,529 and recurrent DVT in the same segment
of a prior DVT contributes most signiﬁcantly to this
process.530
Current well-established evidence-based guidelines
are available from the 2012 American College of Chest
Physicians guidelines.522 Referral to this document for
details and references, as the evidence-based recommenda-
tions are thorough, is recommended. There are several
salient points for the treatment of acute DVT to summa-
rize. First, rapid parenteral anticoagulation with either
low-molecular-weight heparin or fondaparinux is indicated
over intravenous unfractionated heparin (Grade 1A), as this
may increase DVT recanalization.531 Second, early use of
compression is recommended, generally within 24 hours
of diagnosis (Grade 2C). Third, early ambulation and
limiting of bed rest are recommended.532 Fourth,
Guideline 8.5: Primary PreventiondOperative
Therapy
In patients with asymptomatic C1-2 disease from
either primary or secondary causes, we suggest against
prophylactic interventional therapies to prevent venous
leg ulcer. [GRADE - 2; LEVEL OF EVIDENCE - C]
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with at least 3-month treatment is the minimum duration.
In certain cases, consideration of the new oral anticoagu-
lants, such as factor IIa or Xa oral inhibitors, may be indi-
cated if the patient is intolerant of warfarin, although the
evidence for these agents is less well documented.533
Last, a recent RCT suggests that low-dose aspirin may
decrease recurrent DVT in those treated initially with 6
to 12 months of parenteral anticoagulation.534
Recent data, primarily from one study, suggest that
low-molecular-weight heparin for 3 months may be more
effective than a vitamin K antagonist for preventing PTS,
with signiﬁcantly fewer ulcers observed during 1 year of
follow-up.535 A systemic review also suggested that low-
molecular-weight heparin may decrease VLUs at 3 months
byw87%.536 More evidence is needed to conﬁrm these re-
sults, and whether the new oral anticoagulants offer antiﬁ-
brotic beneﬁts remains unproven.
Long-term therapeutic anticoagulation is associated
with lower DVT recurrence rates and, depending on the
clinical circumstances of recurrence risk vs bleeding risk,
should direct the duration of therapy.522 An adjunctive
measure to determine duration of anticoagulation is the
measurement of D-dimer 1 month after cessation of anti-
coagulation. An RCT showed that if a patient’s D-dimer
level remains elevated, venous thromboembolism recur-
rence risk is signiﬁcantly elevated (w2.5-fold), and contin-
uation or reinstitution of anticoagulation is recommended,
usually for life.537 If the D-dimer level is normal, cessation
of anticoagulation is usually safe. Second, use of duplex ul-
trasonography for detection of residual vein wall thickening
or obstruction (scar tissue, or “residual thrombus”) may be
beneﬁcial, although the evidence is more variable in the
literature, varying from 2.5- to 9.7-fold increased
risk.538,539 If a patient has an extensively irregular or
occluded long segment of vein, this may be a marker for
increased risk of recurrent DVT, and thus continued anti-
coagulation may be beneﬁcial.
Last, the use of catheter-directed thrombolysis
compared with best medical therapy may signiﬁcantly
decrease PTS. The recent CaVenT trial compared best
medical therapy with adjunctive catheter-directed throm-
bolysis in an RCT of patients with iliofemoral DVT.540
In 209 patients, the absolute risk reduction at 24 months
was 14.4% (0.2%-28%) in PTS reduction, as assessed by Vil-
lalta score. However, several occurrences of major bleeding
did occur, offsetting some of the beneﬁt. In properly
selected patients, the beneﬁt of catheter-directed throm-
bolysis outweighs the risks, particularly with modern cath-
eter thrombus removal techniques and experienced
practitioners.541Guideline 8.4: Primary PreventiondEducation
Measures
In patients with C1-4 disease, we suggest patient
and family education, regular exercise, leg elevation
when at rest, careful skin care, weight control, and
appropriately ﬁtting foot wear. [BEST PRACTICE]In patients with C3 and C4 disease of primary valvular
reﬂux or C1-C4 disease related to DVT, we recommend
regular ambulation or equivalent exercise, leg elevation
when in bed or recumbent, good skin care to maintain
skin moisture and to prevent drying and cracking, and foot-
wear that is well ﬁtted. Leg elevation is effective in patients
with C4 disease by increasing microcirculatory ﬂow.542
Although employing only a surrogate measure, a pro-
spective study of exercise in 20 patients showed similar re-
sults in C5 patients, with an improvement in calf muscle
pump function.543 A structured review also suggested a
positive effect of exercise (ambulation) on calf muscle
pump function, although not directly assessed for VLU
occurrence.443 An RCT of structured exercise with 31 pa-
tients with C3 or higher clinical class venous disease
showed improved calf muscle pump function compared
with no speciﬁc exercise.492 It is not uncommon for pa-
tients to have both venous reﬂux and diabetes, and stan-
dard guidelines in foot care for diabetics have been
produced.544
Evidence for all these measures in preventing VLU is
weak. In consideration of shoe types, one study suggested
that high heels may decrease hydrostatic pressure at the an-
kles.545 A separate study using air plethysmography showed
that high heels were associated with decreased ejection
fraction and increased residual volume fraction.546 Howev-
er, speciﬁc footwear and risk of VLU has not been tested,
but caution should be exercised in those with C3 or higher
clinical class venous disease. One study also suggested that
correction of pedal podalic angle with special insoles may
increase the calf muscle pump function.547
No data exist for educational interventions in those
with CVI to prevent VLU. However, the cost of and risk
to patients and family education are likely to be reasonable,
with little potential for harm. Knowledge of family history
of maternal venous reﬂux is important as a prognostic factor
for development of VLU.513 Moreover, education of care-
givers who interact with patients with C1 to C4 disease
is equally important. It is recommended that all vascular
specialists make the effort to educate primary caregivers.In patients with C1-2 disease from either primary or
secondary causes, it is unclear if interventional therapies
prevent long-term VLU occurrence, in contrast to good
supporting evidence for surgery and VLU recurrence. A
direct link between early treatment of superﬁcial venous
reﬂux and long-term VLU incidence is only circumstantial.
In a large study from Nelzen, a 50% reduction in VLU was
found to correlate with a better diagnosis and treatment of
superﬁcial disease.21 Whereas there have been no trials
assessing primary VLU prevention in those with C1-2
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vention decrease recurrent VLU.288 Similarly, there is no
evidence that prophylactic repair of the deep venous
valvular system can decrease long-term VLUs in those pa-
tients who have not manifested any such entity.
The goal of surgical treatments should be to improve
the patient’s symptoms, including leg pain, swelling, and
discomfort. To achieve this goal, numerous interventions
exist for treatment of superﬁcial venous disease as well as
deep system disease for secondary prevention of VLU,
speciﬁed in the section on operative/endovascular manage-
ment and in other guidelines for comprehensive manage-
ment of superﬁcial venous disease.23
FUTURE DIRECTIONS/CONCLUSIONS
The SVS/AVF Evidence-Based Clinical Practice
Guidelines for Management of Venous Leg Ulcers is the
end result of a programmatic initiative by the AVF “to
reduce the incidence of venous ulcer 50% over the next
decade”29 combined with the need for clinical practice
guidelines for VLUs, as recognized by the SVS Document
Oversight Committee. With the primary target audience
for these guidelines, specialists who treat VLUs, the current
guidelines attempt to update as well as to address gaps in
prior VLU guidelines. A recent systematic analysis of exist-
ing VLU guidelines demonstrated concordance in certain
areas but signiﬁcant management gaps in others, such as
advanced wound therapies, role of thermal ablation of su-
perﬁcial venous disease, valve reconstruction, and treat-
ment of outﬂow obstruction by stenting, all of which
were not addressed in previous guideline documents.18 To-
ward that end, formal new systematic review and meta-
analyses were performed for two areas, compression and
surgical/endovascular treatments.30,31
The current SVS/AVF clinical practice guidelines are
based on the best level of evidence currently available for
a recommendation. The strength of a recommendation
for a speciﬁc guideline is tempered by the quality of evi-
dence supporting that recommendation. The SVS/AVF
Joint Clinical Practice Guidelines Committee has reviewed
the grading of recommendations within each sub-
committee and as an overall group with an eye toward a
critical assessment. Overall, the evidence level for venous
ulcer management is mostly of moderate strength, and as
a consequence, most recommendations as a whole achieve
lower grades, Grade 2B (18.6%) and Grade 2C (53.3%); in
some instances, the recommendations may not be graded
and are designated Best Practice (10.7%). Parenthetically
it should be noted that the current American College of
Chest Physicians guidelines for antithrombotic therapy
and prevention of thrombosis contain no Grade 1A recom-
mendations.522 This observation points to the need for
more well-done randomized controlled studies on the
management of VLUs. Whereas the current VLU guide-
lines attempt to cover the state of evidence as it exists
today, as more evidence comes to fruition, updates and
modiﬁcations will be required on an ongoing basis, so
that these VLU guidelines become “living documents.”The treatment of VLU currently is hampered by a siloed
approach, that is, just focusing on ulcer healing or ulcer
recurrence rather than on the continuum of care. For
expressing and assessing cost/resource utilization as well
as quality of outcomes, how long the skin remains in an
ulcer-free state (ulcer-free interval), as expressed by the
percentage of the follow-up period that the skin is ulcer
free, is a more valuable metric.
Key points from the current guidelines and areas of
evidence needed to assist with future directions for VLU
management are summarized as follows.
Venous Ulcer Deﬁnition and Pathophysiology
A classiﬁcation system of VLU into meaningful groups
in which comparative studies with different treatments can
be carried out is needed. This is necessary and cogent
because there is such diversity of disease entities under
the broad term venous ulcer. Pure venous ulcer: Reﬂux
into ulcer region by any route superﬁcial or perforator or
deep without identiﬁable additional disease. Mixed venous
ulcer: Reﬂux or obstruction creating venous hypertension
in region of venous ulcer in presence of identiﬁable addi-
tional disease.
Additional pathologic processes that are risk factors for
venous disease need to be categorized, such as arterial
occlusive disease, infection, inﬂammatory (dermatitis,
allergic, autoimmune), lymphedema, and morbid obesity.
Each of these disease processes presents additional barriers
that may require separate adjunctive treatment for the ulcer
to heal. If untreated, they can prolong healing even after
correction of venous reﬂux.
The study of the inﬂammatory cascade that allows
benign reﬂux to cause tissue changes leading to and
becoming VLU needs to be expanded. Understanding of
why some patients who have varicosities down to the ankle
associated with long-standing venous reﬂux can convert to
CEAP C4b-C6 severity is missing. If the cause is inﬂamma-
tion, then speciﬁc treatment of the inﬂammatory problem
with steroids or other measures may need to be included
in addition to correction of the reﬂux or obstruction.
Clinical Evaluation
The current management of VLU depends on accurate
identiﬁcation and assessment of the presence of venous dis-
ease underlying wound behavior. Accurate anatomic and
functional venous and wound classiﬁcation is required.
Whereas duplex ultrasound is an essential tool in achieving
venous disease diagnosis, additional imaging modalities that
aid in assessing wound biology and the physiologic impact
of wound and venous disease therapy are needed. The role
of outﬂow imaging for patients with suspected iliocaval ste-
nosis/occlusion requires further development. Additional
validation of venous disease and wound classiﬁcation systems
and quality outcome measures is needed to allow better
comparative analysis evidence of therapeutic modalities.
Wound Care. The wound care ﬁeld continues to
evolve and expand. Drivers include an aging society,
increasing prevalence of obesity and other comorbid
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new treatment technologies. The current VLU guidelines
address the most important clinical issues surrounding
advanced wound care, including wound bed preparation,
control of bacterial colonization and infection, and
débridement techniques and frequency, which are all crit-
ical to achieving healing outcomes. Novel diagnostic
methods under development for the rapid identiﬁcation
of bacteria and inﬂammatory cytokine levels will likely
result in the need for additional comparative effectiveness
research in the near future for clinicians to decide on best
practice options. Use of these diagnostic modalities may
allow patient-speciﬁc therapeutics to enhance the potential
for rapid wound healing.
A broad range of therapeutic modalities employing
various forms of electromagnetic energy transfer may be
used adjunctively for the healing of chronic wounds.
Currently, there is a lack of standardization concerning en-
ergy settings, treatment frequency, and methods of energy
delivery, making ﬁrm recommendations difﬁcult. There are
more treatments under evaluation presently, with some
methods combining energy sources. These data will need
to be evaluated in future updates. Last, there has been
recent expansion of cellular and acellular biologic dressings.
These products can be human or animal derived and come
in myriad formats. Currently, there are no comparative
effectiveness studies available to help guide the clinician
to make appropriate decisions on use of these products. Ev-
idence in this expanding ﬁeld will need to be evaluated so
that populations of patients who would beneﬁt the most
from speciﬁc tissue products can be identiﬁed. A signiﬁcant
role for patient-centered outcomes measures also needs to
be incorporated into trial design in the future. The pa-
tient’s preferences will need to be balanced with clinical ef-
ﬁcacy and economic factors in the face of health care
reform.
Compression
The use of compression has been a fundamental treat-
ment component for VLU, but certain knowledge gaps still
exist. Objective measures of the “dose” of compression
should be used in future studies. These measures, which
include resting interface pressure at a standard point and
stiffness (change in this pressure during standing and
walking), need to be factored into compression effective-
ness. These objective measures should replace such current
classiﬁcations as “elastic” and “inelastic” bandages, espe-
cially for multibandage systems. The real behavior of a
bandage and bandage system is not the elastic property
tested in the laboratory but its clinical behavior on the leg.
Even a single bandage applied with overlaps becomes a
multilayer wrap with different mechanical properties. The
friction between multiple layers increases stiffness of the
wraps, especiallywhen the surface of a component is adhesive
or cohesive and when substances like zinc paste are used.
In assessing the role of compression, there are other
needs. Standard training with objective quality controlshould be used in studies of bandages and bandage sys-
tems; most of the comparative studies to date were per-
formed in centers inexperienced with short-stretch
material. A large-scale RCT is needed to study whether
compression prevents the recurrence of venous ulcers.
The role of IPC in treatment of venous ulcer patients needs
to be deﬁned, especially in patients who cannot tolerate
compression therapy or who have failed to respond to pro-
longed compression therapy alone. Finally, methods for
assessing the patient’s compliance with wearing of these
garments/devices that are better than “patient diaries”
should be developed. These monitoring devices are being
employed in the treatment of other diseases, like the dia-
betic foot.
Operative/Endovascular. Unfortunately, the quality
of evidence to support recommendations for operative
and endovascular management is limited to level C evi-
dence. This lower level of evidence is due to the absence
of comparative prospective RCTs, with the exception of
a few studies that address treatment of superﬁcial venous
disease. Even the data in the treatment of superﬁcial
insufﬁciency, as suggested by the commissioned meta-
analysis, are limited in scope. The data derived from
open procedures (ligation and stripping RCTs) have been
extrapolated to results that might be achieved with
thermal ablation. Future investigations need to address
this deﬁciency in a meaningful way to push the ﬁeld
forward.
Many recommendations regarding healed patients or
patients with potential VLU are based on extrapolations
from the data obtained from patients with active VLUs.
Each speciﬁc patient condition needs focused investigation
to determine what “best care” is. Several methods of great
and small saphenous ablation are under investigation and
may provide even less risk for the beneﬁts provided.
Many in the venous community have reserved deep
venous reconstruction for those cases in which nothing
else has been successful. This treatment option has been
a forgotten therapeutic alternative for a growing popula-
tion of patients with deep venous insufﬁciency in whom
nonsurgical and superﬁcial venous intervention has been
unsuccessful. Because of the ease of other interventions
or a misguided assumption, there is room to reinvestigate
this assumption by comparing repair of deep venous insuf-
ﬁciency vs outﬂow obstruction interventions in patients
who have both conditions.
Ancillary. Ancillary measures to improve ulcer healing
include adequate nutrition to provide sufﬁcient vitamins,
minerals, and protein to support the growth of granulation
tissue. Whereas pentoxifylline and micronized puriﬁed
ﬂavonoid fraction, both in combination with compression
therapy, have demonstrated a beneﬁcial effect on ulcer
healing, these medications are not widely used. Better un-
derstanding of the pathophysiologic mechanism of the
VLU may help develop other novel systemic or local treat-
ment. Physiotherapy is a useful ancillary measure to VLU
healing as it improves calf muscle pump function and
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moderate-quality evidence that increased physical activity,
improved mobility, and foot exercises decrease VLU
recurrence, but more standardization is required.
Primary Prevention. Cost-effectiveness of VLU pre-
vention is difﬁcult to rigorously prove owing to the
requirement for large patient numbers in these trials and
the heterogeneous nature of CVI. Adequate compression
in a compliant patient with C1-C4 disease and the use of
evidence-based therapies for treatment with prevention of
DVT recurrence should go a long way toward decreasing
the incidence of VLU. Although much information is
available to patients online and by other sources, dissemi-
nation of preventive measures to front-line physicians and
advanced practice providers is critical for reaching the most
patients possible at risk of VLU.
As for all clinical classes of CVI, there is a knowledge
gap as to whether adequate compression and skin care
or, alternatively, surgical intervention for superﬁcial venous
incompetence prevents progression to another clinical dis-
ease level, speciﬁcally from C4 to C6.REFERENCES
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